<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Piperacillin and tazobactam: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Piperacillin and tazobactam: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Piperacillin and tazobactam: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11250" href="/d/html/11250.html" rel="external">see "Piperacillin and tazobactam: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12708" href="/d/html/12708.html" rel="external">see "Piperacillin and tazobactam: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F210401"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zosyn</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F210424"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Penicillin</li></ul></div>
<div class="block doa drugH1Div" id="F210405"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Adult doses are expressed as the combined amount of piperacillin and tazobactam. Infusion method: Dosing is presented based on the traditional infusion method over 30 minutes, unless otherwise specified as the extended or continuous infusion method (off-label methods).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Traditional infusion method (over 30 minutes):</i>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate infection: 3.375 g every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe infection: 4.5 g every 6 to 8 hours (limited data for every 8 hours frequency; refer to indication-specific dosing below) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14979482','lexi-content-ref-21896561','lexi-content-ref-19832720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14979482','lexi-content-ref-21896561','lexi-content-ref-19832720'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pseudomonas aeruginosa </i>infection: 4.5 g every 6 hours. Usual maximum dose: 18 g/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended-infusion method (off-label method):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 3.375 or 4.5 g every 8 hours infused over 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17205441','lexi-content-ref-19809009','lexi-content-ref-25575030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17205441','lexi-content-ref-19809009','lexi-content-ref-25575030'])">Ref</a></span>). <b>Note:</b> A loading dose of 3.375 to 4.5 g over 30 minutes can be given, especially when rapid attainment of therapeutic drug concentrations is necessary (eg, sepsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34599691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous-</i>
<i>infusion method (off-label method):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 18 g infused over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26754759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26754759'])">Ref</a></span>); may give a loading dose of 4.5 g over 30 minutes, especially when rapid attainment of therapeutic drug concentrations (eg, sepsis) is desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26754759','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26754759','lexi-content-ref-34599691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended and continuous infusion methods are based largely on pharmacokinetic and pharmacodynamic modeling data; clinical efficacy data are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26754759','lexi-content-ref-17205441','lexi-content-ref-24359838','lexi-content-ref-Moehring.2019a','lexi-content-ref-24867788','lexi-content-ref-29102324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26754759','lexi-content-ref-17205441','lexi-content-ref-24359838','lexi-content-ref-Moehring.2019a','lexi-content-ref-24867788','lexi-content-ref-29102324'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b74db564-f66e-4f55-8b58-9759dc214a0c">Bite wound infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, treatment (animal or human bite) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 3.375 g every 6 to 8 hours. Duration of treatment for established infection (which may include oral step-down therapy) is typically 5 to 14 days. Additional coverage for methicillin-resistant <i>Staphylococcus aureus</i> may be needed for empiric treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2019b','lexi-content-ref-Baddour.2019a','lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2019b','lexi-content-ref-Baddour.2019a','lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection</b>
<b>(gram-negative bacteremia) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For empiric therapy of known or suspected gram-negative (including <i>P. aeruginosa</i>) bloodstream infection in patients with neutropenia, severe burns, sepsis, or septic shock, some experts recommend giving piperacillin and tazobactam in combination with a second gram-negative active agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.1','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.1','lexi-content-ref-34599691'])">Ref</a></span>). Some experts also prefer extended or continuous infusions for critical illness or when treating a susceptible organism with an elevated minimum inhibitory concentration (MIC) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2019a','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2019a','lexi-content-ref-34599691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Community-acquired infection</i>, <i>immunocompetent host:</i>
<b>IV:</b> 3.375 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2019b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Health care-associated infection,</i>
<i>including catheter-related, immunosuppressed host, or for coverage of</i>
<i>P. aeruginosa</i>: <b>IV:</b> 4.5 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710','lexi-content-ref-Moehring.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710','lexi-content-ref-Moehring.2019b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> Usual duration is 7 to 14 days, depending on source, pathogen, extent of infection, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2019b'])">Ref</a></span>); a 7-day duration is recommended for patients with uncomplicated Enterobacteriaceae infection who respond appropriately to antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29190320','lexi-content-ref-Moehring.2019b','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29190320','lexi-content-ref-Moehring.2019b','lexi-content-ref-30535100'])">Ref</a></span>). <b>Note:</b> If neutropenic, extend treatment until afebrile for 2 days and neutrophil recovery (ANC ≥500 cells/mm<sup>3</sup> and increasing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094'])">Ref</a></span>). For <i>P. aeruginosa</i> bacteremia in neutropenic patients, some experts treat for a minimum of 14 days and until recovery of neutrophils (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d05d7443-d11a-4d5f-98b9-5df276676f75">Cystic fibrosis, severe acute pulmonary exacerbation or failure of oral therapy, for coverage of <i>P. aeruginosa</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, severe acute pulmonary exacerbation or failure of oral therapy, for coverage of <i>P. aeruginosa</i></b>
<b>(off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4.5 g every 6 hours usually as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669','lexi-content-ref-Simon.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669','lexi-content-ref-Simon.2019'])">Ref</a></span>). <b>Note:</b> Some experts prefer the extended or continuous infusion method to optimize exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23869050','lexi-content-ref-Simon.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23869050','lexi-content-ref-Simon.2019'])">Ref</a></span>). Duration is usually 10 to 14 days, depending on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669','lexi-content-ref-34469706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669','lexi-content-ref-34469706'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d3e4522-e8bc-4496-b3e0-f1fcdd0f13d7">Diabetic foot infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, moderate to severe: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 3.375 g every 6 hours <b>or</b> 4.5 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21896561','lexi-content-ref-19832720','lexi-content-ref-8215266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21896561','lexi-content-ref-19832720','lexi-content-ref-8215266'])">Ref</a></span>). For treatment of <i>P. aeruginosa </i>infection: 4.5 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weintrob.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weintrob.2017'])">Ref</a></span>). <b>Note: </b>Duration (which may include oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.2017'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute:</i>
<b>IV:</b> 3.375 g or 4.5 g every 6 hours; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infection (eg, cholangitis, perforated appendix, diverticulitis, intra-abdominal abscess):</i>
<b>IV:</b> 3.375 g or 4.5 g every 6 hours. Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2019','lexi-content-ref-Pemberton.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2019','lexi-content-ref-Pemberton.2019'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>). <b>Note:</b> For patients who are critically ill or at risk for infection with drug-resistant pathogens, some experts favor the extended infusion method (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2019','lexi-content-ref-28484510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2019','lexi-content-ref-28484510'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve 4.5 g dose for health care-associated infection, severe community-acquired infection, or patients with community-acquired infection at high risk of adverse outcome and/or resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2019','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2019','lexi-content-ref-20034345'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2f24db8-ac24-430f-af0c-d53a2eaf8458">Malignant external otitis, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant (necrotizing) external otitis, hospitalized patients</b>
<b>(alternative agent) (off-label use)</b>: <b>IV:</b> 4.5 g every 6 hours. Total duration of therapy, including oral step-down, is 6 to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grandis.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grandis.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c5b7d31-660e-465f-9563-41ed8ee77b0d">Neutropenic fever, high-risk patients with cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, high-risk patients with cancer (empiric therapy)</b>
<b>(off-label use)</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> High-risk patients are those expected to have an ANC ≤100 cells/mm<sup>3</sup> for &gt;7 days <b>or</b> an ANC ≤100 cells/mm<sup>3 </sup>for any expected duration if there are ongoing comorbidities (eg, sepsis, mucositis, significant hepatic or renal dysfunction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094'])">Ref</a></span>); some experts use an ANC cutoff &lt;500 cells/mm<sup>3</sup> to define high-risk patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wingard.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wingard.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4.5 g every 6 to 8 hours until afebrile for ≥48 hours and resolution of neutropenia (ANC ≥500 cells/mm<sup>3</sup> and increasing) or standard duration for the specific infection identified, if longer than the duration for neutropenia. If there is significant concern for <i>Pseudomonas</i> infection (particularly in those who are severely ill or were not receiving fluoroquinolone prophylaxis), 4.5 g every 6 hours should be given. Additional agent(s) may be needed depending on clinical status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094','lexi-content-ref-Wingard.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094','lexi-content-ref-Wingard.2018'])">Ref</a></span>). Some experts prefer extended or continuous infusion for critical illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2019a','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2019a','lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Community-acquired pneumonia:</i> For empiric therapy of inpatients at risk of infection with a resistant gram-negative pathogen(s), including <i>P. aeruginosa:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 4.5 g every 6 hours as part of an appropriate combination regimen. Total duration (which may include oral step-down therapy) is for a minimum of 5 days; a longer course may be required for patients with an immunocompromising condition, severe or complicated infection, or for <i>P. aeruginosa</i> infection. Patients should be clinically stable with normal vital signs prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-32561442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-32561442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hospital-acquired or ventilator-associated pneumonia:</i> For empiric therapy (often as part of an appropriate combination regimen) or pathogen-specific therapy of resistant gram-negative pathogen(s), including <i>P. aeruginosa:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 4.5 g every 6 hours. Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>). <b>Note:</b> Some experts prefer extended or continuous infusion for critical illness or when treating a susceptible organism with an elevated MIC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2019a','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2019a','lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a74533c8-554a-440e-8601-6b5e9cffeae7">Sepsis and septic shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sepsis and septic shock</b>
<b>(broad-spectrum empiric therapy, including <i>P.</i>
<i>aeruginosa) </i>(off-label use):</b>
<b>IV:</b> 4.5 g every 6 hours in combination with other appropriate agent(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.3'])">Ref</a></span>). Initiate therapy as soon as possible and within 1 hour of recognition of sepsis or septic shock. Duration is dependent on underlying source and patient response; short courses are preferred, when appropriate. Consider discontinuation if a noninfectious etiology is identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34599691'])">Ref</a></span>). Some experts prefer the extended or continuous infusion method (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2019a','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2019a','lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5389b037-d8ce-48e2-98b3-f8bb5a208a34">Skin and soft tissue infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, moderate to severe</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients with necrotizing infections, select surgical-site infections (intestinal, GU tract), or patients with or at risk for gram-negative pathogens (eg, <i>P. aeruginosa) </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>3.375 g every 6 hours <b>or</b> 4.5 g every 8 hours; often used as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>). For treatment of <i>P. aeruginosa</i> infection: 4.5 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.4'])">Ref</a></span>). Usual duration (including oral step-down therapy) is 5 to 14 days based on severity and clinical response; for necrotizing infection, continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for ≥48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Kanj.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Kanj.4'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms) (off-label use):</b>
<b>IV:</b> 3.375 g every 6 hours. <b>Note:</b> Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days; for patients with symptomatic improvement within the first 48 to 72 hours of therapy, some experts recommend shorter courses of 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021','lexi-content-ref-21292654','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021','lexi-content-ref-21292654','lexi-content-ref-30535100'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990471"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Doses are expressed as the combined amount of piperacillin and tazobactam. Infusion method: Dosing is presented based on the traditional infusion method over 30 minutes, unless otherwise specified as the extended infusion method over 4 hours or continuous infusion method over 24 hours (off-label methods). When utilizing extended infusions, a loading dose of 3.375 to 4.5 g over 30 minutes can be given, especially when rapid attainment of therapeutic drug concentrations is necessary (eg, sepsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34599691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Altered kidney function: </b>
<b>IV:</b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Piperacillin/Tazobactam Dosage Adjustments in Altered Kidney Function<sup>a,b</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center"></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Traditional infusion method (over 30 minutes)</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Extended infusion method (over 4 hours)</b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 3.375 g every 6 hours</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>If the usual recommended dose is 4.5 g every 6 hours</b></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 3.375 g infused over 4 hours every 8 hours</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Choose the usual recommended dose based on indication and disease severity (see adult dosing), then choose the adjusted dose from that column corresponding to the patient's CrCl.</p></td></tr>
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>Patel 2010; Thabit 2017; expert opinion; manufacturer's labeling.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">100 to &lt;130</p></td>
<td align="center">
<p style="text-indent:0em;">Extended infusion preferred</p></td>
<td align="center">
<p style="text-indent:0em;">Extended infusion preferred</p></td>
<td align="center">
<p style="text-indent:0em;">3.375 <b> or </b>4.5 g infused over 4 hours every 6 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">40 to &lt;100 (usual recommended dose)</p></td>
<td align="center">
<p style="text-indent:0em;">3.375 g every 6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">4.5 g every 6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">3.375 g infused over 4 hours every 8 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20 to &lt;40</p></td>
<td align="center">
<p style="text-indent:0em;">2.25 g every 6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">4.5 g every 8 hours <b>or</b> 3.375 g every 6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">3.375 g infused over 4 hours every 8 to 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;20</p></td>
<td align="center">
<p style="text-indent:0em;">2.25 g every 8 hours</p></td>
<td align="center">
<p style="text-indent:0em;">4.5 g every 12 hours <b>or</b> 2.25 g every 6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">3.375 g infused over 4 hours every 12 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): </b>Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns or hematological malignancies. An 8 to 24 hour measured urinary creatinine clearance is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 130 to &lt;170 mL/minute: <b>IV:</b> 4.5 g every 6 hours infused over 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>) <b>or</b> Loading dose: 4.5 g, followed immediately by a daily continuous infusion of 18 g over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30172963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30172963'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥170 mL/minute: <b>IV:</b> Loading dose: 4.5 g, followed immediately by a daily continuous infusion of 22.5 g over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30172963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30172963'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (30% to 40%):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4.5 g every 12 hours <b>or </b>2.25 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29121839','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29121839','lexi-content-ref-Manu.1'])">Ref</a></span>); administration of scheduled doses after hemodialysis on dialysis days is preferred but not required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzable (6% of piperacillin, 21% of tazobactam):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4.5 g every 12 hours <b>or</b> 2.25 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2324971','lexi-content-ref-11216560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2324971','lexi-content-ref-11216560'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24674926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24674926'])">Ref</a></span>). Recommendations assume high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (~1,500 to 3,000 mL/hour), unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24612982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24612982'])">Ref</a></span>)) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: <b>Note:</b> Given piperacillin/tazobactam’s favorable safety profile, some experts recommend initiating therapy with relatively high doses (especially in critically ill patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20636224','lexi-content-ref-25881872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20636224','lexi-content-ref-25881872'])">Ref</a></span>). Dose should be adjusted during CRRT interruptions as ongoing dosing may lead to accumulation and potential increased risk of toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4.5 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15647409','lexi-content-ref-23908259','lexi-content-ref-Shotwell.2016','lexi-content-ref-24612982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15647409','lexi-content-ref-23908259','lexi-content-ref-Shotwell.2016','lexi-content-ref-24612982'])">Ref</a></span>) <b>or </b>4.5 g loading dose followed by 2.25 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25881872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25881872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: 4.5 g loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>) followed immediately by a 9 g over 24 hours daily maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25881872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25881872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Sustained low-efficiency dialysis (8-hour daily sessions with blood flow rate 200 mL/minute and effluent flow rate 300 mL/minute): 3.375 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29730948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29730948'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended high-volume hemofiltration (10-hour sessions with blood flow rate 200 mL/minute and effluent flow rate &gt;500 mL/minute): 4.5 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26830215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26830215'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987725"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doo drugH1Div" id="F54962832"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, or 3 obesity (BMI ≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended infusion method (off-label method): Note: </b>To increase the likelihood of therapeutic concentrations and target attainment. When rapid attainment of therapeutic drug concentrations is necessary, use a loading dose of 4.5 g over 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34599691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Life-threatening infections caused by less-susceptible pathogens (eg, minimum inhibitory concentration [MIC] 16 mg/L); or infection site penetration limitations; or patients with extreme morbid obesity (BMI ≥50 kg/m<sup>2</sup>):</i>
<b>IV:</b> 4.5 g every 6 hours infused over 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28052849','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28052849','lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Critically ill patients with augmented renal clearance:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Measured urinary CrCl 130 to &lt;170 mL/minute:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 4.5 g every 6 hours infused over 3 hours <b>or</b> Loading dose: 4.5 g, followed immediately by a daily continuous infusion of 18 g over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Measured urinary CrCl ≥170 mL/minute:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Continuous infusion regimen is recommended to optimize therapeutic concentrations and target attainment (expert opinion).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> Loading dose: 4.5 g, followed immediately by a daily continuous infusion of 22.5 g over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30172963','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30172963','lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Traditional infusion method (over 30 minutes): IV:</b> 4.5 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28869666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28869666'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">There are limited data evaluating the effect of obesity on dosing requirements for piperacillin and tazobactam. Data are available from hospitalized patients (eg, critically ill) predominantly at steady state concentrations. Consistently lower unbound trough concentrations and increased drug clearance estimates and volume of distribution (with greater coefficients of variation) are reported in patients who are obese compared with patients who are not obese (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26702922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26702922'])">Ref</a></span>). Despite a higher proportion of patients who are obese who have subtherapeutic trough concentrations (eg, due to augmented renal clearance, elevated pathogen MIC [MIC ≥16 mg/L]), administration of higher doses (eg, 4.5 g every 6 hours) may increase drug concentrations and the likelihood of target concentration attainment, particularly when administered as a prolonged infusion (eg, over 3 to 4 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28052849','lexi-content-ref-23228881','lexi-content-ref-24956136','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28052849','lexi-content-ref-23228881','lexi-content-ref-24956136','lexi-content-ref-Expert.DOO'])">Ref</a></span>). The effect of obesity on first-dose pharmacokinetics remains unknown.</p></div>
<div class="block doe drugH1Div" id="F210406"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F210418"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12708" href="/d/html/12708.html" rel="external">see "Piperacillin and tazobactam: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Zosyn (piperacillin/tazobactam) is a combination product that contains piperacillin sodium and tazobactam sodium in an 8:1 ratio; for every 1,000 mg of piperacillin there is 125 mg of tazobactam, which is equivalent to 1,125 mg of total piperacillin and tazobactam. Dosage recommendations are based on the <b>piperacillin</b> component. Dosing is presented in mg/kg/dose and mg/kg/<b>day</b>; use caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent infusion method (eg, 30-minute infusion):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≤6 months: IV: 240 to 300 mg piperacillin/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum daily dose: 16 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>). Based on pharmacokinetic modeling, 75 to 80 mg/kg/dose every 4 hours has been recommended to improve exposure for pathogens with higher minimum inhibitory concentrations (MICs) (eg, 16 mg/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24614369','lexi-content-ref-31427292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24614369','lexi-content-ref-31427292'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &gt;6 months, Children, and Adolescents: IV: 240 to 300 mg piperacillin/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum daily dose: 16 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>). <b>Note: </b>Based on pharmacokinetic modeling, intermittent dosing every 8 hours may be suboptimal, particularly for infections caused by bacteria with MICs ≥2 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34029707','lexi-content-ref-19422028','lexi-content-ref-31427292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34029707','lexi-content-ref-19422028','lexi-content-ref-31427292'])">Ref</a></span>). Higher total daily doses are recommended for some indications (eg, pneumonia, cystic fibrosis, neutropenic fever) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23907263','lexi-content-ref-30740885','lexi-content-ref-22696019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23907263','lexi-content-ref-30740885','lexi-content-ref-22696019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended infusion dosing (eg, 4-hour infusion):</i> Limited data available: Children and Adolescents: IV: 100 mg piperacillin/kg/dose infused over 3 to 4 hours every 6 to 8 hours; maximum daily dose: 16 <b>g</b>/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23907263','lexi-content-ref-28638304','lexi-content-ref-26552978','lexi-content-ref-AAP.2021','lexi-content-ref-22696019','lexi-content-ref-36186238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23907263','lexi-content-ref-28638304','lexi-content-ref-26552978','lexi-content-ref-AAP.2021','lexi-content-ref-22696019','lexi-content-ref-36186238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous infusion dosing</i>: Very limited data available: Infants ≥6 months, Children, and Adolescents: IV: Initial loading dose: 75 mg piperacillin/kg infused over 30 minutes, followed by 300 mg piperacillin/kg/<b>day</b> infused over 24 hours; maximum daily dose: 16 <b>g</b>/<b>day</b>. Dosing from an observational pharmacokinetic and safety study in critically ill patients; due to potential risk for overexposure, therapeutic drug monitoring is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36422708']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36422708'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d1d4c54-ef98-486f-9c71-c0e9856532b2">Cystic fibrosis, acute pulmonary exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, acute pulmonary exacerbation:</b>
<b>Note: </b>Optimal dose may vary based on disease severity, susceptibility patterns (eg, minimum inhibitory concentration), or patient tolerability. Treatment duration varies and is dependent on patient-specific factors including response to therapy; typical duration is 10 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31487382','lexi-content-ref-34588142','lexi-content-ref-27139161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31487382','lexi-content-ref-34588142','lexi-content-ref-27139161'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Standard dose</i>: IV: 240 to 400 mg piperacillin/kg/<b>day</b> divided every 8 hours, infused over 30 minutes or 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Egan.1','lexi-content-ref-36593628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Egan.1','lexi-content-ref-36593628'])">Ref</a></span>); others have used 350 to 400 mg/kg/<b>day</b> divided every 4 hours in early piperacillin trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22949297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22949297'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>High dose</i>: Limited data available: IV: 450 mg piperacillin/kg/<b>day</b> divided every 4 to 6 hours or 600 mg piperacillin/kg/<b>day</b> divided every 4 hours has been described in studies of piperacillin alone; usual maximum daily dose: 18 to 24 <b>g</b> piperacillin/<b>day</b>. <b>Note:</b> Piperacillin doses &gt;600 mg/kg/<b>day</b> or an extended duration of therapy (&gt;14 days) have been associated with dose-related adverse effects, including serum sickness, immune-mediated hemolytic anemia, and bone marrow suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22949297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22949297'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da36b131-13ff-4e28-b905-1acb141aff64">Endocarditis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis: </b>Children and Adolescents: IV: 240 mg piperacillin/kg/<b>day</b> divided every 8 hours in combination with an aminoglycoside for at least 6 weeks; maximum daily dose: 18 <b>g</b> piperacillin/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>). <b>Note:</b> Based on pharmacokinetic/pharmacodynamic data for piperacillin/tazobactam, guideline dosing may be suboptimal and not achieve the desired targets needed to treat endocarditis; a higher total daily dose given more frequently (~300 mg piperacillin/kg/<b>day</b> divided every 6 hours) has been suggested; extended infusion (eg, infuse over 3 to 4 hours) is recommended when using every-8-hour dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26917819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26917819'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b> Infants, Children, and Adolescents: IV: 240 to 300 mg piperacillin/kg/<b>day</b> divided every 6 to 8 hours. Doses up to 400 mg piperacillin/kg/<b>day</b> divided every 6 hours have been reported. Maximum dose: 4,000 mg piperacillin/dose; some experts suggest that 3,000 mg piperacillin/dose is adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34132703','lexi-content-ref-11714046','lexi-content-ref-24650475','lexi-content-ref-33340867','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34132703','lexi-content-ref-11714046','lexi-content-ref-24650475','lexi-content-ref-33340867','lexi-content-ref-28085573'])">Ref</a></span>). Duration dependent upon age, source of infection, and surgical status. Typical duration is 4 to 7 days unless source control inadequate; in some circumstances (ie, acute or gangrenous appendicitis without perforation managed with surgery), therapy should be limited to ≤24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c3ec306-657e-4501-9d5f-691c697a0b55">Neutropenic fever, empiric treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, empiric treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent infusion:</i> Infants, Children, and Adolescents: IV: 300 to 400 mg piperacillin/kg/<b>day</b> in divided doses every 6 hours, infused over 30 to 60 minutes; maximum dose: 4,000 mg piperacillin/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33170417','lexi-content-ref-30740885','lexi-content-ref-29624028','lexi-content-ref-31222911','lexi-content-ref-31448789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33170417','lexi-content-ref-30740885','lexi-content-ref-29624028','lexi-content-ref-31222911','lexi-content-ref-31448789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous infusion</i>: Children and Adolescents: IV: Initial loading dose: 75 to 100 mg piperacillin/kg infused over 2 to 30 minutes, followed by 300 mg piperacillin/kg/<b>day</b> infused over 24 hours; maximum daily dose: 16 <b>g</b>/<b>day</b>. Based on pharmacokinetic modeling, continuous infusion improves exposure for pathogens with higher minimum inhibitory concentrations (MICs) as compared to intermittent infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23629023','lexi-content-ref-34796702','lexi-content-ref-31448789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23629023','lexi-content-ref-34796702','lexi-content-ref-31448789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Duration of empiric therapy is typically until blood cultures are negative at 48 hours and patient has been clinically well and afebrile ≥24 hours with evidence of marrow recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36689694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36689694'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ba4d4412-a155-49ca-8ebd-47486ba5bb56">Pneumonia, nosocomial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, nosocomial: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants 2 to 9 months: IV: 320 mg piperacillin/kg/<b>day</b> in divided doses every 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;9 months, Children, and Adolescents: IV: 400 mg piperacillin/kg/<b>day</b> in divided doses every 6 hours; maximum dose: 4,000 mg piperacillin/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Data on optimal duration of treatment in children are lacking; however, in adults with hospital-acquired or ventilator-associated pneumonia, 7 days of therapy is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="29d4e108-46ce-4be8-bd73-a5bb3e8f3de1">Skin and soft tissue infection, necrotizing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, necrotizing:</b> Infants, Children, and Adolescents: IV: 240 to 300 mg piperacillin/kg/<b>day </b>in divided doses every 6 hours as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>). Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours; this typically results in a treatment duration of 2 to 3 weeks. Step-down to oral therapy may be considered after improvement in signs and symptoms of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-WHO.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-WHO.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa0c29cc-2f2a-4e1e-b44e-a4d5839ef72e">Surgical antimicrobial prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical antimicrobial prophylaxis</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 2 to 9 months: IV: 80 mg piperacillin/kg within 60 minutes prior to surgical incision; may repeat in 2 hours for prolonged procedure or excessive blood loss (eg, &gt;1,500 mL in adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;9 months, Children, and Adolescents weighing ≤40 kg: IV: 100 mg piperacillin/kg within 60 minutes prior to surgical incision; may repeat in 2 hours for prolonged procedure or excessive blood loss (eg, &gt;1,500 mL in adults). Maximum dose: 3,000 mg piperacillin/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents weighing &gt;40 kg: IV: 3,000 mg piperacillin within 60 minutes prior to surgical incision; may repeat in 2 hours for prolonged procedure or excessive blood loss (eg, &gt;1,500 mL in adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51153609"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing is based on pharmacokinetic parameters, limited pediatric studies, adult studies, and expert opinion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007','lexi-content-ref-23907263','lexi-content-ref-26552978','lexi-content-ref-29121839','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007','lexi-content-ref-23907263','lexi-content-ref-26552978','lexi-content-ref-29121839','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Piperacillin/Tazobactam Dosage Adjustments in Altered Kidney Function<sup>a, b, c</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left"></th>
<th align="left" colspan="4">
<p style="text-indent:0em;">Traditional infusion method (over 30 minutes)</p></th>
<th align="left">
<p style="text-indent:0em;">Extended infusion method (over 3 to 4 hours)</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>a</sup> Choose usual recommended dose based on indication and disease severity (see "Dosing: Pediatric"), then choose the adjusted dose from that column corresponding to the patient's eGFR.</p>
<p style="text-indent:0em;">
<sup>b</sup> Maximum dose: 4,000 mg/dose.</p>
<p style="text-indent:0em;">
<sup>c</sup> When targeting pathogens with elevated minimal inhibitory concentrations (MICs), consider dose needed for normal renal function in addition to severity and site of infection; consider monitoring serum concentrations if available.</p>
<p style="text-indent:0em;">
<sup>d</sup> For dose recommendations &gt;400 mg/kg/day, use clinical judgment (eg, assessment of risks and benefits) to make patient-specific dose adjustment if kidney function is altered; consider therapeutic drug monitoring if available.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left"></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">If the usual recommended dose is 200 to 300 mg/kg/<b>day</b></p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">If the usual recommended dose is 300 to 400 mg/kg/<b>day</b>
<sup>d</sup></p></td>
<td align="left">
<p style="text-indent:0em;">If the usual recommended dose is 300 to 400 mg/kg/<b>day</b>
<sup>d</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">eGFR</p></td>
<td align="left">
<p style="text-indent:0em;">Usual dose: 67 to 100 mg piperacillin/kg/dose every 8 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Usual dose: 50 to 75 mg piperacillin/kg/dose every 6 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Usual dose: 100 to 133 mg piperacillin/kg/dose every 8 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Usual dose: 75 to 100 mg piperacillin/kg/dose every 6 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Usual dose: 100 mg piperacillin/kg/dose infused over 3 to 4 hours every 6 to 8 hours<sup>c</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥40 mL/minute/1.73 m<sup>2</sup> (usual recommended dose)</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20 to &lt;40 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">45 to 70 mg piperacillin/kg/dose every 8 hours</p></td>
<td align="left">
<p style="text-indent:0em;">35 to 50 mg piperacillin/kg/dose every 6 hours</p></td>
<td align="left">
<p style="text-indent:0em;">70 to 90 mg piperacillin/kg/dose every 8 hours</p></td>
<td align="left">
<p style="text-indent:0em;">50 to 70 mg piperacillin/kg/dose every 6 hours</p></td>
<td align="left">
<p style="text-indent:0em;">70 mg piperacillin/kg/dose infused over 3 to 4 hours every 8 hours<sup>c</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;20 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">45 to 70 mg piperacillin/kg/dose every 12 hours</p></td>
<td align="left">
<p style="text-indent:0em;">35 to 50 mg piperacillin/kg/dose every 8 hours</p></td>
<td align="left">
<p style="text-indent:0em;">70 to 90 mg piperacillin/kg/dose every 12 hours</p></td>
<td align="left">
<p style="text-indent:0em;">50 to 70 mg piperacillin/kg/dose every 8 hours</p></td>
<td align="left">
<p style="text-indent:0em;">70 mg piperacillin/kg/dose infused over 3 to 4 hours every 12 hours<sup>c</sup></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Dialyzable: 30% to 40% of administered drug removed by dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 50 to 100 mg piperacillin/kg/dose every 12 hours; administer scheduled doses after hemodialysis on dialysis days if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007','lexi-content-ref-14969569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007','lexi-content-ref-14969569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzable: ~6% piperacillin and 21% tazobactam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 50 to 100 mg piperacillin/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and ultrafiltration rates of 68 mL/kg/hour unless otherwise noted; flow rates vary widely in pediatric patients. Appropriate dosing requires consideration of drug penetration to site of infection, MIC of bacteria, and severity of illness. Close monitoring of response and adverse reactions due to drug accumulation (eg, neurotoxicity) is important. Due to minimal data in pediatric patients receiving CRRT, consider monitoring serum concentrations (eg, trough concentration) if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent infusion</i>: IV: 100 mg piperacillin/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35390523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35390523'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion</i>: IV: 200 mg piperacillin/kg/dose infused over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35390523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35390523'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations that results in increased drug elimination. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28640009','lexi-content-ref-29441476','lexi-content-ref-30374606','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28640009','lexi-content-ref-29441476','lexi-content-ref-30374606','lexi-content-ref-20000886'])">Ref</a></span>). When available, consider utilizing extended infusion due to higher probability of attaining pharmacodynamic targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29862466','lexi-content-ref-31427292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29862466','lexi-content-ref-31427292'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: GFR ≥130 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Traditional or extended infusion</i>: IV: 100 mg piperacillin/kg/dose every 6 hours; infuse over 3 to 4 hours if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29862466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29862466'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion</i>: IV: Loading dose: 100 mg piperacillin/kg infused over 30 minutes, followed by 400 mg/kg/dose infused over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29862466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29862466'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51153610"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants ≥2 months, Children, and Adolescents: No dosing adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F54384460"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection, including <b>
<i>Clostridioides difficile-</i>associated diarrhea</b> and <b>
<i>Clostridioides difficile</i> colitis</b>, has been reported with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29272341'])">Ref</a></span>). Clinical symptoms range from mild diarrhea to life-threatening colitis, toxic megacolon, and sepsis. With severe infection, frequent symptoms include watery diarrhea, abdominal pain, fever, nausea, anorexia, and malaise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19209277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19209277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; antibiotics disrupt the indigenous gut microbiota which promotes <i>C. difficile</i> spore germination, growth, and toxin production, leading to epithelial damage and colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24503131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24503131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Antibiotic exposure (highest risk factor); antibiotics most frequently associated with <i>C. difficile </i>include clindamycin, fluoroquinolones, and third-/fourth-generation cephalosporins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Long duration in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Advanced age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Immunocompromised conditions or serious underlying conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Antiulcer medications, such as proton pump inhibitors and H2 blockers (suggested risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Chemotherapy (suggested risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug-induced immune thrombocytopenia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Drug-induced<b> immune thrombocytopenia </b>(DITP) has been associated with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29863943','lexi-content-ref-26260647','lexi-content-ref-27670947','lexi-content-ref-27073426','lexi-content-ref-22778457','lexi-content-ref-26684560','lexi-content-ref-OUHSC.2015','lexi-content-ref-28784558','lexi-content-ref-25609660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29863943','lexi-content-ref-26260647','lexi-content-ref-27670947','lexi-content-ref-27073426','lexi-content-ref-22778457','lexi-content-ref-26684560','lexi-content-ref-OUHSC.2015','lexi-content-ref-28784558','lexi-content-ref-25609660'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; piperacillin may act as a hapten by binding to the platelet membrane and forming a drug-platelet complex, leading to synthesis of drug-dependent antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29863943','lexi-content-ref-26684560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29863943','lexi-content-ref-26684560'])">Ref</a></span>); drug-dependent antibodies may then bind to platelet membrane glycoproteins, causing platelet consumption and thrombocytopenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27670947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27670947'])">Ref</a></span>). Another proposed mechanism is drug-induced production of antibodies which then bind to the membrane protein in the presence of the soluble drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29863943','lexi-content-ref-23845922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29863943','lexi-content-ref-23845922'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; DITP generally occurs within 1 to 2 weeks after initiating therapy or after intermittent use for a longer time (Alzaharani 2018). Case reports have described an onset from 4 days to &gt;21 days, with a median onset of 6.5 days following initial continuous exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19802882','lexi-content-ref-25609660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19802882','lexi-content-ref-25609660'])">Ref</a></span>). Rapid onset (within 12 to 24 hours) has also been reported very rarely, although most of these were in the setting of reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25609660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25609660'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Myelosuppression (<b>bone marrow depression</b>), commonly manifested as <b>neutropenia</b>, has been associated with piperacillin. Other less commonly reported manifestations include <b>leukopenia</b>, <b>thrombocytopenia </b>(nonimmune), <b>agranulocytosis</b>, and <b>pancytopenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Darwiche.2017','lexi-content-ref-31428326','lexi-content-ref-8645807','lexi-content-ref-23826789','lexi-content-ref-12791166','lexi-content-ref-22505967','lexi-content-ref-8982034','lexi-content-ref-22746695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Darwiche.2017','lexi-content-ref-31428326','lexi-content-ref-8645807','lexi-content-ref-23826789','lexi-content-ref-12791166','lexi-content-ref-22505967','lexi-content-ref-8982034','lexi-content-ref-22746695'])">Ref</a></span>). Rarely, piperacillin-induced platelet dysfunction leading to <b>epistaxis</b> or serious bleeding events, such as <b>intracranial hemorrhage </b>(periprocedural), has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29555607','lexi-content-ref-3488418','lexi-content-ref-3975759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29555607','lexi-content-ref-3488418','lexi-content-ref-3975759'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; mechanism behind neutropenia is unknown; suggested to be immune-mediated or the result of direct toxicity to the myeloid precursors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22746695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22746695'])">Ref</a></span>). Bleeding events have been attributed to platelet dysfunction (or platelet aggregation), rather than thrombocytopenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29555607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29555607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; neutropenia was found to only occur after &gt;15 days of therapy in a systematic review (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17408306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17408306'])">Ref</a></span>); other literature suggests it may occur after ≥10 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12791166','lexi-content-ref-22746695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12791166','lexi-content-ref-22746695'])">Ref</a></span>); has also been observed after 3 days of therapy in a patient 91-years of age in 1 case report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Darwiche.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Darwiche.2017'])">Ref</a></span>). Neutropenia is usually reversible upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khan2005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khan2005'])">Ref</a></span>) and total blood counts reportedly returned to normal 4 days after discontinuation in 1 case report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23826789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23826789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10624596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10624596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High cumulative doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10624596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10624596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underweight patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8982034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8982034'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Delayed hypersensitivity reactions, including severe cutaneous adverse reactions (SCARs), such as <b>toxic epidermal necrosis </b>(TEN), <b>Stevens-Johnson syndrome </b>(SJS),<b> acute generalized exanthematous pustulosis</b>, and<b> drug rash with eosinophilia and systemic symptoms </b>(DRESS), have been reported. SJS, TEN, and DRESS may be life-threatening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25668894','lexi-content-ref-32042284','lexi-content-ref-24599767','lexi-content-ref-21690532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25668894','lexi-content-ref-32042284','lexi-content-ref-24599767','lexi-content-ref-21690532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic; SCARs are type IV delayed T-cell mediated hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32042284','lexi-content-ref-24599767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32042284','lexi-content-ref-24599767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; type IV reactions typically occur 2 to 7 days after drug exposure, but may also not occur for several weeks following exposure, such as with TEN (2 to 3 weeks) or DRESS (2 to 8 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25668894','lexi-content-ref-23855313','lexi-content-ref-21690532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25668894','lexi-content-ref-23855313','lexi-content-ref-21690532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cystic fibrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33444815','lexi-content-ref-7924483','lexi-content-ref-24169544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33444815','lexi-content-ref-7924483','lexi-content-ref-24169544'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Piperacillin, an extended spectrum beta-lactam antibiotic of the acylaminopenicillin group, may cause hypersensitivity reactions (type I reactions), including <b>anaphylaxis</b> and <b>anaphylactic shock</b>, which are considered immediate hypersensitivity reactions (vs delayed reactions) and are IgE-mediated. These reactions can manifest as <b>pruritus</b>, <b>flushing</b>, urticaria, angioedema, bronchospasm, laryngeal edema, abdominal distress, <b>hypotension</b>, and/or anaphylactic shock or <b>anaphylaxis</b>, and are potentially life-threatening. Of note, some of these, such as pruritus, urticaria, or angioedema, may also occur in delayed hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25623506','lexi-content-ref-17620077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25623506','lexi-content-ref-17620077'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic. Type I reactions are IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25124380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25124380'])">Ref</a></span>). There are also reports of piperacillin/tazobactam-induced anaphylaxis in patients with negative penicillin skin tests, suggesting a side chain determinant of piperacillin, rather than the beta-lactam component (or possibly the tazobactam component), was responsible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17620077','lexi-content-ref-10955713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17620077','lexi-content-ref-10955713'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; type 1 reactions usually occur within 1 hour of administration but may occur up to 6 hours after the last dose. Selected type 1 hypersensitivity reactions (eg, urticaria, angioedema, wheezing, laryngeal edema) may occur up to 4 days into therapy but within 1 to 6 hours from the last administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25623506','lexi-content-ref-25124380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25623506','lexi-content-ref-25124380'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Frequent, repeated exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6491103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6491103'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of beta-lactam hypersensitivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6491103','lexi-content-ref-1467132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6491103','lexi-content-ref-1467132'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of sensitivity to multiple allergens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6491103','lexi-content-ref-1467132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6491103','lexi-content-ref-1467132'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Occupational exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21603168','lexi-content-ref-29383926','lexi-content-ref-21532862']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21603168','lexi-content-ref-29383926','lexi-content-ref-21532862'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cystic fibrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33444815','lexi-content-ref-7924483','lexi-content-ref-24169544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33444815','lexi-content-ref-7924483','lexi-content-ref-24169544'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Observational studies involving predominately noncritically ill adults have suggested a higher rate of <b>nephrotoxicity</b> or acute kidney injury (AKI, or acute kidney failure) when piperacillin/tazobactam is given in combination with vancomycin compared to either agent alone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29649586','lexi-content-ref-24855041','lexi-content-ref-32040830','lexi-content-ref-26476979','lexi-content-ref-27784223','lexi-content-ref-29442542','lexi-content-ref-28182801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29649586','lexi-content-ref-24855041','lexi-content-ref-32040830','lexi-content-ref-26476979','lexi-content-ref-27784223','lexi-content-ref-29442542','lexi-content-ref-28182801'])">Ref</a></span>); however, evidence is primarily of low quality and controversy regarding this association exists. In critically ill patients, limited data have been inconsistent regarding an increased risk of AKI with the combination of piperacillin/tazobactam and vancomycin; additional data are needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30172962','lexi-content-ref-26952639','lexi-content-ref-29088001','lexi-content-ref-30741072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30172962','lexi-content-ref-26952639','lexi-content-ref-29088001','lexi-content-ref-30741072'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; one proposed mechanism is piperacillin/tazobactam may cause subclinical interstitial nephritis which is augmented by the oxidative stress induced by vancomycin; another proposed mechanism is piperacillin/tazobactam may potentially decrease the clearance of vancomycin, leading to vancomycin accumulation within the nephron. However, there is no experimental evidence to support either of these hypotheses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29020249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29020249'])">Ref</a></span>). Of note, evidence also suggests that piperacillin/tazobactam alone is associated with delayed recovery of renal function in critically ill patients and reversible nephrotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22411933','lexi-content-ref-31210955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22411933','lexi-content-ref-31210955'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; median duration of combination therapy with piperacillin/tazobactam and vancomycin prior to the development of AKI was 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986669'])">Ref</a></span>). Another study reported a peak incidence at day 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27067325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27067325'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Piperacillin/tazobactam combined with vancomycin:</p>
<p style="text-indent:-2em;margin-left:8em;">• Vancomycin loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27067325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27067325'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant nephrotoxins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27067325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27067325'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Durations of empirical therapy &gt;72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27067325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27067325'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Increased total body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31369116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31369116'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Piperacillin is reportedly less neurotoxic than penicillin; however, there are case reports of piperacillin-induced <b>encephalopathy</b> (PIPE) characterized by dysarthria, tremor, slurred speech, auditory and visual hallucinations, behavioral changes, disorientation, progressive confusion, and generalized<b> tonic-clonic seizures</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21501212','lexi-content-ref-19499182','lexi-content-ref-17496739','lexi-content-ref-25098503','lexi-content-ref-26400582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21501212','lexi-content-ref-19499182','lexi-content-ref-17496739','lexi-content-ref-25098503','lexi-content-ref-26400582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Beta-lactam-induced neurotoxicity is attributed to the lactam ring, which is believed to exert an inhibitory effect on binding of the gamma-aminobutyric acid (GABA) to its receptor; this theory is further supported by studies showing the epileptogenic potential is lost when the beta-lactam ring is enzymatically cleaved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21501212','lexi-content-ref-25098503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21501212','lexi-content-ref-25098503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Risk factors for antibiotic-induced neurotoxicity in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Renal dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21501212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21501212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior CNS disease, including history of seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21501212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21501212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21501212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21501212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Critically-ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21501212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21501212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19499182','lexi-content-ref-17496739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19499182','lexi-content-ref-17496739'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F210369"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see Piperacillin monograph.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (≤1%), hypotension (≤1%), phlebitis (1%), thrombophlebitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (3%), skin rash (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1%), <i>Clostridioides difficile</i> colitis (≤1%), constipation (8%), dyspepsia (3%), nausea (7%), vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Purpuric disease (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (8%), insomnia (7%), rigors (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤1%), myalgia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin, decreased serum glucose, decreased serum total protein, electrolyte disorder (increases and decreases in sodium, potassium, and calcium), hyperglycemia, hypokalemia, increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, eosinophilia, positive direct Coombs test, prolonged bleeding time, prolonged partial thromboplastin time, prolonged prothrombin time</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Peermohamed 2011), dermatologic disorder (linear IgA bullous dermatosis) (Ho 2018), erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome (Lin 2014), toxic epidermal necrolysis (Copaescu 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile-</i>associated diarrhea (Watson 2018), melanoglossia (Ren 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (He 2013), bone marrow depression (He 2013), hemolytic anemia (Bollotte 2014), hemophagocytic lymphohistiocytosis (Miyabayashi 2018), immune thrombocytopenia (Boyce 2016), leukopenia (Reichardt 1999), neutropenia (Darwiche 2017), pancytopenia (Lee 2009), thrombocytopenia (Kumar 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency (He 2013), hepatitis (Kraleti 2016), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, drug reaction with eosinophilia and systemic symptoms (Cabañas 2014), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Serum sickness-like reaction (Linares 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium (Tong 2004), encephalopathy (Grill 2011), intracranial hemorrhage (periprocedural) (Bower 2018), tonic-clonic seizure (Lin 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Kadomura 2019), interstitial nephritis (Liu 2012), nephrotoxicity (Kadomura 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis (García-Moguel 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Drug fever (Linares 2011)</p></div>
<div class="block coi drugH1Div" id="F210385"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to penicillins, cephalosporins, beta-lactamase inhibitors, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F210366"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte abnormalities: Sodium content (2.8 mEq per gram of piperacillin) should be considered in patients requiring sodium restriction. Assess electrolytes periodically in patients with low potassium reserves.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment or in hemodialysis patients. Dosage adjustment recommended.</p></div>
<div class="block foc drugH1Div" id="F210378"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zosyn: Piperacillin 2 g and tazobactam 0.25 g per 50 mL (50 mL); Piperacillin 4 g and tazobactam 0.5 g per 100 mL (100 mL); Piperacillin 3 g and tazobactam 0.375 g per 50 mL (50 mL) [contains edetate (edta) disodium dihydrate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Piperacillin 12 g and tazobactam 1.5 g (1 ea); Piperacillin 36 g and tazobactam 4.5 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zosyn: Piperacillin 2 g and tazobactam 0.25 g (1 ea [DSC]); Piperacillin 3 g and tazobactam 0.375 g (1 ea [DSC]); 4.5 g: Piperacillin 4 g and tazobactam 0.5 g (1 ea [DSC]); 2.25 g: Piperacillin 2 g and tazobactam 0.25 g (1 ea [DSC]); 40.5 g: Piperacillin 36 g and tazobactam 4.5 g (1 ea [DSC]); 3.375 g: Piperacillin 3 g and tazobactam 0.375 g (1 ea [DSC]) [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g (1 ea); 3.375 g: Piperacillin 3 g and tazobactam 0.375 g (1 ea); 4.5 g: Piperacillin 4 g and tazobactam 0.5 g (1 ea); 40.5 g: Piperacillin 36 g and tazobactam 4.5 g (1 ea); Piperacillin 12 g and tazobactam 1.5 g (1 ea); Piperacillin 2 g and tazobactam 0.25 g (1 ea); Piperacillin 3 g and tazobactam 0.375 g (1 ea); Piperacillin 36 g and tazobactam 4.5 g (1 ea); Piperacillin 4 g and tazobactam 0.5 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F210362"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F6856652"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Zosyn Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-0.25 gm/50 mL (per mL): $0.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3-0.375 gm/50 mL (per mL): $0.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4-0.5 g/100 mL (per mL): $0.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Piperacillin Sod-Tazobactam So Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.25 (2-0.25) g (per each): $3.59 - $14.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.375 (3-0.375) g (per each): $3.60 - $21.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.5 (4-0.5) g (per each): $6.73 - $27.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13.5 (12-1.5) g (per each): $27.60 - $78.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40.5 (36-4.5) g (per each): $78.00 - $206.16</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55787065"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Piperacillin 12 g and tazobactam 1.5 g (1 ea); Piperacillin 2 g and tazobactam 0.25 g (1 ea); Piperacillin 3 g and tazobactam 0.375 g (1 ea); Piperacillin 36 g and tazobactam 4.5 g (1 ea); Piperacillin 4 g and tazobactam 0.5 g (1 ea)</p></div>
<div class="block adm drugH1Div" id="F210382"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer by IV infusion over 30 minutes. For extended infusion administration (off-label method), administer over 3 or 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28052849','lexi-content-ref-19809009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28052849','lexi-content-ref-19809009'])">Ref</a></span>). For continuous infusion method (off-label method), administer total dose (18 g) over 24 hours as a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26754759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26754759'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Limited retrospective data with IV push administration over 2 to 5 minutes (vial reconstituted with NS [10 mL for a 3.375 g vial and 20 mL for a 4.5 g vial] or SWFI [20 mL for a 2.25 g, 3.375 g, or 4.5 g vial]) have demonstrated this method of administration to be generally safe and tolerable, but clinical outcomes were not assessed; patients should be monitored for phlebitis and other infusion-related reactions if administered IV push (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32470139','lexi-content-ref-30190292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32470139','lexi-content-ref-30190292'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides in vitro. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy in vivo, particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered. <b>Note:</b> Reformulated Zosyn containing EDTA has been shown to be compatible in vitro for Y-site infusion with amikacin and gentamicin diluted in NS or D5W (applies <b>only</b> to specific concentrations and varies by product; consult manufacturer’s labeling). Reformulated Zosyn containing EDTA is <b>not</b> compatible with tobramycin.</p></div>
<div class="block admp drugH1Div" id="F52613599"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Administer over 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended IV infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonatal: Administer over 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27644691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27644691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric: Administer over 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28638304','lexi-content-ref-26552978','lexi-content-ref-36186238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28638304','lexi-content-ref-26552978','lexi-content-ref-36186238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer total daily dose over 24 hours as a continuous infusion. If a loading dose is used, administer over 2 to 30 minutes prior to initiation of the continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36422708','lexi-content-ref-23629023','lexi-content-ref-34796702','lexi-content-ref-31448789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36422708','lexi-content-ref-23629023','lexi-content-ref-34796702','lexi-content-ref-31448789'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F210381"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection: </b>Treatment of appendicitis complicated by rupture or abscess and peritonitis in adults and pediatric patients ≥2 months of age caused by beta-lactamase-producing strains of <i>Escherichia coli</i>, <i>Bacteroides fragilis</i>, <i>Bacteroides ovatus</i>, <i>Bacteroides thetaiotaomicron</i>, or <i>Bacteroides vulgatus</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic infection:</b> Treatment of postpartum endometritis or pelvic inflammatory disease in adults caused by beta-lactamase-producing strains of <i>E. coli</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b> Treatment of moderate severity community-acquired pneumonia in adults caused by beta-lactamase-producing strains of <i>Haemophilus influenzae</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired (nosocomial):</b> Treatment of moderate to severe hospital-acquired (nosocomial) pneumonia in adults and pediatric patients ≥2 months of age caused by beta-lactamase-producing strains of <i>Staphylococcus aureus</i> and by piperacillin/tazobactam-susceptible <i>Acinetobacter baumannii</i>, <i>H. influenzae</i>, <i>Klebsiella pneumoniae</i>, and <i>Pseudomonas aeruginosa</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b> Treatment of skin and soft tissue infection, including cellulitis, cutaneous abscess, and ischemic/diabetic foot infection, in adults caused by beta-lactamase-producing strains of <i>S. aureus</i>.</p></div>
<div class="block off-label drugH1Div" id="F25470612"><span class="drugH1">Use: Off-Label: Adult</span><p>Bite wound infection, treatment (animal or human bite); Bloodstream infection (gram-negative bacteremia); Cystic fibrosis, severe acute pulmonary exacerbation; Malignant (necrotizing) external otitis; Neutropenic fever, high-risk patients with cancer (empiric therapy); Sepsis and septic shock; Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms)</p></div>
<div class="block mst drugH1Div" id="F210432"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Zosyn may be confused with Zofran, Zyvox.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tazact [India] may be confused with Tazac brand name for nizatidine [Australia]; Tiazac brand name for dilTIAZem [US, Canada].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299884"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F210371"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OAT1/3 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: OAT1/3 Inhibitors may increase the serum concentration of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucloxacillin: Piperacillin may increase the serum concentration of Flucloxacillin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Betalactamase Inhibitors. Management: Coadministration of probenecid with amoxicillin/clavulanate is not recommended per official package labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Piperacillin may enhance the nephrotoxic effect of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vecuronium: Piperacillin may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F210387"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Piperacillin and tazobactam cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of piperacillin/tazobactam may be altered (Bourget 1998).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).</p>
<p style="text-indent:0em;margin-top:2em;">Piperacillin/tazobactam is approved for the treatment of postpartum gynecologic infections, including endometritis or pelvic inflammatory disease, caused by susceptible organisms. Untreated intraamniotic infection (chorioamnionitis) may lead to adverse pregnancy outcomes including pneumonia, meningitis, and sepsis in the newborn. Maternal complications may include postpartum uterine atony with hemorrhage, endometritis, peritonitis, sepsis, or adult respiratory distress syndrome. Piperacillin/tazobactam is an alternative option for the treatment of intraamniotic infection (ACOG 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Piperacillin/tazobactam is considered compatible with pregnancy when used for the treatment airway diseases, such as cystic fibrosis, in pregnant women (ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block brc drugH1Div" id="F210388"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Piperacillin is present in breast milk; information for tazobactam is not available.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Piperacillin/tazobactam is considered compatible with breastfeeding in women when used for the treatment of airway diseases, such as cystic fibrosis. Bioavailability is expected to be low if ingested orally (eg, via breast milk); however, intestinal absorption may be increased in neonates (ERS/TSANZ [Middleton 2020]). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush and diarrhea (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F210389"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F210376"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Creatinine, BUN, hematologic parameters (especially with prolonged [≥21 days] use; eg, CBC with differential, PT, PTT), serum electrolytes, LFTs, urinalysis; signs of bleeding; monitor for signs of anaphylaxis during first dose, if a skin rash develops monitor closely, CNS effects.</p></div>
<div class="block pha drugH1Div" id="F210365"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Piperacillin inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Piperacillin exhibits time-dependent killing. Tazobactam inhibits many beta-lactamases, including staphylococcal penicillinase and Richmond-Sykes types 2, 3, 4, and 5, including extended spectrum enzymes; it has only limited activity against class 1 beta-lactamases other than class 1C types.</p></div>
<div class="block phk drugH1Div" id="F210384"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Both AUC and peak concentrations are dose proportional.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Well into lungs, intestinal mucosa, uterus, ovary, fallopian tube, interstitial fluid, gallbladder, and bile; penetration into CSF is low in subjects with noninflamed meninges</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Piperacillin:</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates and Infants &lt;2 months: Steady state: Median: 0.42 L/kg (Cohen-Wolkowiez 2014)</p>
<p style="text-indent:-2em;margin-left:8em;">Infants 2 to 5 months: Single dose: 0.37 ± 0.1 L/kg (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:8em;">Infants 6 months to Children &lt;6 years: Single dose: 0.36 ± 0.1 L/kg (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to 12 years: Single dose: 0.36 ± 0.2 L/kg (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Critically ill children 9 months to 6 years have been shown to have higher V<sub>d</sub> of 0.511 ± 0.366 L/kg (Cies 2014)</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents and Adults: 0.243 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Piperacillin: ~26% to 33%; Tazobactam: 31% to 32%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism:</p>
<p style="text-indent:-2em;margin-left:4em;">Piperacillin: 6% to 9% to desethyl metabolite (weak activity)</p>
<p style="text-indent:-2em;margin-left:4em;">Tazobactam: ~22% to inactive metabolite</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: IM: Piperacillin: 71%; Tazobactam: 84%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Piperacillin:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates and Infants &lt;2 months: Median: 3.5 hours; range: 1.7 to 8.9 hours (Cohen-Wolkowiez 2014)</p>
<p style="text-indent:-2em;margin-left:6em;">Infants 2 to 5 months: 1.4 ± 0.5 hours (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children 6 to 23 months: 0.9 ± 0.3 hours (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 5 years: 0.7 ± 0.1 hours (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to 12 years: 0.7 ± 0.2 hours (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.7 to 1.2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Metabolite: 1 to 1.5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Tazobactam:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants 2 to 5 months: 1.6 ± 0.5 hours (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children 6 to 23 months: 1 ± 0.4 hours (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 5 years: 0.8 ± 0.2 hours (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to 12 years: 0.9 ± 0.4 hours (Reed 1994)</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.7 to 0.9 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Immediately following completion of 30-minute infusion</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance of both piperacillin and tazobactam are directly proportional to renal function</p>
<p style="text-indent:-2em;margin-left:4em;">Piperacillin: Urine (68% as unchanged drug); feces (10% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Tazobactam: Urine (80% as unchanged drug; remainder as inactive metabolite)</p></div>
<div class="block phksp drugH1Div" id="F51219295"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Half-life increases 2-fold for piperacillin and 4-fold for tazobactam in patients with CrCl &lt;20 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Piperacillin (in combination with tazobactam): Time dependent; associated with free time (<i>f</i>T) &gt; minimum inhibitory concentration (MIC); goal: ≥50% <i>f</i>T &gt; MIC (bactericidal) (Lodise 2006). In critically ill patients in the ICU, minimum goal: ≥50% <i>f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% <i>f</i>T &gt; 4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Tazobactam (in combination with piperacillin): Time dependent, associated with <i>f</i>T &gt; MIC, goal: ≥77% <i>f</i>T &gt; MIC (1-log kill) (Pogue 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug concentrations in patients with normal renal function</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients: C<sub>max</sub> (peak): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">30-minute infusion, single dose: Piperacillin 100 mg/tazobactam 12.5 mg per kg: Infants ≥2 months of age and children ≤12 years of age: Piperacillin: 360 mg/L; tazobactam: 39 mg/L (Reed 1994).</p>
<p style="text-indent:-2em;margin-left:8em;">4-hour infusion, multiple dose: Piperacillin 100 mg/tazobactam 12.5 mg per kg every 8 hours: Children ≤9 years of age: Piperacillin: 119.9 ± 36.3 mg/L; tazobactam: 17.6 ± 5.1 mg/L (Nichols 2016a).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: C<sub>max</sub> (peak): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Adult doses are expressed as the combined amount of piperacillin and tazobactam.</p>
<p style="text-indent:-2em;margin-left:8em;">30-minute infusion, multiple dose:</p>
<p style="text-indent:-2em;margin-left:10em;">2.25 g every 6 hours: Piperacillin: 134 mg/L; tazobactam: 15 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">3.375 g every 6 hours: Piperacillin: 242 mg/L; tazobactam: 24 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">4.5 g every 6 hours: Piperacillin: 298 mg/L; tazobactam: 34 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">4-hour infusion, multiple dose: 4.5 g every 8 hours: Piperacillin: 108.2 ± 31.7 mg/L; tazobactam: 21.7 ± 7.8 mg/L (Shea 2009b).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Generally little to no postantibiotic effect (&lt;1 hour) for gram-negative bacilli (including <i>P. aeruginosa</i>) (Craig 1991; Craig 1998; Li 1997).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with toxicity:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Continuous infusion: Critically ill adults: A piperacillin serum concentration of 157.2 mg/L was associated with neurotoxicity (Quinton 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent infusion: Hospitalized adults: Piperacillin C<sub>min </sub>&gt;361.4 mg/L associated with 50% risk of developing neurotoxicity; piperacillin C<sub>min </sub>&gt;452.65 mg/L associated with 50% risk of developing nephrotoxicity (evaluated by increases in serum creatinine) (Imani 2017).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F210390"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lintaz | Prizma | Tazocin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bagotaz | Fada piperacilina tazobactam | Petezam | Piperac | Piperac+tazobactam richet | Piperacilin | Piperacilina tazobactam drawer | Piperacilina tazobactam northia | Piperacilina+Tazobactam Norgreen | Tazonam | Vredian</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/Tazobactam Actavis | Piperacillin/tazobactam arcana | Piperacillin/Tazobactam Ibigen | Piperacillin/tazobactam kabi | Piperacillin/tazobactam sandoz | Piperacillin/Tazobactam Stragen | Pipetazan | Pipitaz | Tazonam</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">DBL Piperacillin and Tazobactam | Piperacillin/ tazobactam kabi | Pipertaz | Piptaz | Piptaz aft | Tazocin | Tazopip</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Brodactam | Megacilin | Tazocil | Tazocilin | Tazopen | Tazosyn</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin tazobactam ab | Piperacillin/Tazobactam Actavis | Piperacilline / Tazobactam Mylan | Piperacilline / Tazobactam Sandoz | Piperacilline/tazobactam sandoz | Piperacilline/Tazobactam Teva | Tazocin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/ tazobactam kabi | Piperacillin/Tazobactam Actavis | Pipetazon | Tazocin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Novataz | Piperacilina sodica + tazobactam sodico | Piperacilina sodica e tazobactam sodico | Piperazam | Tazocin | Tazomaz | Tazoxil | Tazpen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Piperacilin/Tazobactam Labatec | Piperacillin/tazobactam fresenius | Piperacillin/Tazobactam Mylan | Piperacillin/tazobactam sandoz | Piperacillin/Tazobactum Mylan</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Aurotaz p | Piperacilline/tazobactam sandoz | Tazocilline</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Pipetazo | Tazonam | Tratac</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An di tai | Bang da | Feng tai ling | Hai ta xin | Kai ke jia | Kai lun | Kang de li | Pai ta qiang | Piperacillin sodium and tazobactam sodium | Piperacillin sodium and tazobactam sodium (4:1) for Injection | Piperacillin/tazo. | Rui yang yong kang | Tazobactam sodium and piperacillin sodium | Tazocin | Xian tai</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aurotaz p | Delbactam | Genobactam | Kabictam | Nirpclin tz | Penibectam | Piperacilina + tazobactam | Piperacilina y Tazobactam | Piperacilina+tazobactam | Piperacilina/tazobactam | Piperacillin + Tazobactam | Piperacillin/tazobactam | Pipertazo | Pipetax | Piprocira | Piptabac | Pixamol | Salataz | Smalka | Sumimed pipertazo | Tapectam | Tazocin | Tazrobida</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam | Piperacillin/tazobactam aurobindo | Piperacillin/Tazobactam Mylan | Piperacillin/tazobactam olikla | Piperacillin/Tazobactam Pharmaswiss | Piperacillin/Tazobactam Teva | Tazip | Tazocin | Tazopet | Tebranic</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin + Tazobactam Eberth | Piperacillin comp hexal | Piperacillin tazobactam pfizer | Piperacillin Tazobactam Ratiopharm | Piperacillin und Tazobactam ibisqus | Piperacillin/Tazobactam Actavis | Piperacillin/tazobactam aurobindo | Piperacillin/Tazobactam Hexal | Piperacillin/Tazobactam Kabi | Piperacillin/Tazobactam Noridem | Piperacillin/Tazobactam Orchid | Piperacillin/Tazobactam Pfizer | Piperacillin/Tazobactam puren | Piperacillin/Tazobactam Stragen | Piperacillin/Tazobactam Teva | Tazobac | Tazocin | Tazocin ef</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Piperacilina/Tazobactam Sandoz | Piperazam | Suldiazan | Tapectam | Tazocin | Truvesta</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Betampil | Piperacilina y Tazobactam | Piperacilina+tazobactam | Piperazam | Tapectam | Tazocin | Trital</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam aurobindo | Piperacillin/Tazobactam fresenius Kabi | Piperacillin/tazobactam sandoz | Piperacillin/Tazobactam Teva | Tazocin | Tazoject | Tazpen</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Piprataz | Tazocin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Pipera/Tazob Kabi | Piperacilin tazobactam sala | Piperacilina/Tazobactam Accord | Piperacilina/tazobactam actavis | Piperacilina/tazobactam aurovitas | Piperacilina/Tazobactam Combino Pharm | Piperacilina/Tazobactam Domac | Piperacilina/Tazobactam Hospira | Piperacilina/Tazobactam Orchid | Piperacilina/Tazobactam Sandoz | Piperacilina/Tazobactam Stada | Piperacilina/Tazobactam Teva | Tazocel</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Injpip tz | Piperacillin and tazobactam | Piperacillin sodium and tazobactam sodium | Piperacillin/tazobactam | Tazocin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/Tazobactam Fre. Kabi | Piperacillin/Tazobactam Hospira | Piperacillin/Tazobactam Orchid Europe Ltd | Piperacillin/Tazobactam Reig Jofre | Piperacillin/Tazobactam Stragen | Tazocin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin tazobactam pa | Piperacillin tazobactam teva | Piperacilline/tazobactam arrow | Piperacilline/tazobactam hospira | Piperacilline/Tazobactam Kabi | Piperacilline/tazobactam sandoz | Tazocilline</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam | Tazocin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Gramenox | Oliten | Piperacillin+tazobactam/alvia | Piperacillin+Tazobactam/generics | Piperacillin+tazobactam/kabi | Tavoctame | Tazepen | Tazidron | Tazobion | Tazocin | Tazorex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aurotaz p | Tazocin | Tazorex | Tazrobida</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Acipirin | Piperacillin/Tazobactam Pharmaswiss | Tazocin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam kabi | Piperacillin/tazobactam sandoz | Piperan | Tazocin | Zytobakt</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Tazam | Tazocin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin / tazobactam | Piperacillin/tazobactam | Pipercin | Piperin | Tazocin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Tazo pip avenir | Tazocin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">A zobact | Adzopip | Adzopip np | Akazo p | Auxitaz | Axosilin | Biopiper tz | Blucillin tazo | Boosticiline | Brodactam | Cadigard | Capritaz | Cidal | Durataz | Elpip | Eltum | Extentia | Futaz | Glantaz | Goldtaz | Gramotaz | Granipip | Ibipitaz | Imunobact | Infectam | Innobactam | Ipzact | Kilbac | Lintaz | Lupitaz | Lypitaz | Mapeptoz | Maxotaz | Microtaz | Nexlin | Novacillin plus | Olin | Olzup | Pactum | Pepbio tz | Pertum | Picvic | Piczar | Piperacef t | Pipmax | Piprapen-t | Pipras-T | Piprataz | Pipsan t | Piptact | Piptal | Piptalon | Piptamate | Piptaz | Piptazone | Piptoz | Pipzam | Pipzar | Pipzed | Pipzo | Piract | Pirotaz | Pisa | Pitalin | Pitazop | Pitza | Pizobac | Pizofast | Pizowave | Prazobact | Protaz | Pseudostat | Pt | Pt max | Rantaz | Regi pt | Revotaz | Spintaz | Suptaz | Swiftaz | Syntazo | T pep | Tamilin mb | Tapic | Tazact | Tazar | Tazcan | Taze | Tazilin | Tazin | Tazira | Tazo p | Tazo Plus | Tazobac | Tazobactin | Tazocid | Tazocilline | Tazofast | Tazomac | Tazomax | Tazomust | Tazonex | Tazoniche | Tazopen | Tazoper | Tazoren | Tazoset | Tazosure | Tazoter | Tazotop | Tazotum | Tazpen | Te pe | Tezo pc | Tobz | Torbac | Tozabact | Troypipera T | Trucido | Truzol | Tzactum | Viltaz | Vorior | Xtapip | Zepita | Zolsed | Zoop | Zopercin | Zosyn</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ibitazina | Limerik | Piperac+Taz EG | Piperac+Taz Fki | Piperac+taz Ign | Piperacillina e tazobactam kabi | Piperacillina e tazobactam sandoz | Piperacillina e Tazobactam TEVA | Piperacillina/Tazobactam | Repita | Tazobac | Tazocin | Tazopenil | Textazo</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Prizma | Tazocin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Tazocin | Tazopipe | Zosyn</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Apotaz p | Aurotaz p | Injpip tz | Inno zopip | Kilzact | Piptaz | Piptazo | Pipzo | Pitamak | Pizomark | Sinopiptazo | Tazocin ef | Yanoven</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lynbactam | Piperactam | Tabactam | Tabaxin | Taperacin | Taroten | Tazo v | Tazobaxin | Tazocil | Tazocin | Tazofen | Tazolactam | Tazoperan | Uniperatam</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Prizma | Tazocin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam panpharma | Piperacilline/Tazobactam | Prizma | Tazocin | Yanoven</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin plus tazobactam eberth | Piperacillin/Tazobactam Actavis | Piperacillin/tazobactam aurobindo | Piperacillin/tazobactam fresenius | Piperacillin/tazobactam sandoz | Tazocin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Tazocin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam aurobindo | Piperacillin/Tazobactam Teva | Piperacillin/tazobaktam actavis | Piperacillin/tazobaktam hexal | Tazocin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aurotaz p | Lintaz | Piptabac | Tasovak | Tasuprol | Tazocin | Tazocin ef | Tazpen | Vicitalis</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aurotaz p | Piperacillin/tazobactam kabi | Tapicin | Tazocin | Tazpen | Tazrobida</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ciltaz | Piperacillin/tazobactam sandoz | Pipranir tz</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam kabi | Piperacilline/Tazobactam | Piperacilline/tazobactam actavis | Piperacilline/Tazobactam Bipharma | Piperacilline/Tazobactam PCH | Piperacilline/tazobactam sandoz | Tazocin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/Tazobactam FarmaPlus | Piperacillin/tazobactam Fresenius kabi | Piperacillin/Tazobactam Orchid | Piperacillin/Tazobactam Stragen | Piptazira | Tazocin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam | Piptaz aft | Piptaz sandoz | Tazocin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ampitotal | Aurotaz p | Piperacilina + tazobactam | Piperacilina - tazobactam | Pletzolyn | Tapectam | Tazocin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alvotaz | Ampita | Bactaz | Bizataz | Diapiptaz | Du tazop | Dypita | Dyzitam | Endtaz | Gopibac | Kenzolin | Levepipe | Nazovac | Paizu | Pantazo | Peprasan T | Perataz | Philtam | Piperacillin/Tazobactam Hospira | Piperbactam | Pipercil | Piperwell | Pipoz | Piptam | Piptaz | Piptazitam | Piptazone | Pipzo | Pipzolen | Piracil | Piracilin | Pitazolin 4.5 | Pizobac | Pizotaz | Plepra t | Pletzolyn | Prazitam | Rabactam | Racelax | Sudomas | Syprolyd | Tanzo | Tapimycin | Tapipzo | Tazbactam | Tazmane | Tazmar | Tazmed | Tazobak | Tazobal | Tazocin | Tazocure | Tazoget | Tazokab | Tazopen | Tazosar | Tazotaz | Tazovex | Tazovit | Tazpiracil | Tazrobida | Tazur | Tebranic | Tiperaz | Tozarin | Ureitaz | Vactazo | Zobac | Zobacillin | Zopip</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Hicin | Piprabact | Piptaz | Racibact | Tacip | Tanzo | Tazbac | Tazocin | Tazocin ef | Tazonem | Tazopip | Tazostin | Zoycin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam kabi | Piperacillin/Tazobactam Noridem | Piperacillin/tazobactam sandoz | Tazacylin | Tazocin | Tebranic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin and tazobactam | Zosyn</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Piperacilina + tazobactam | Piperacilina + Tazobactam Aurobindo | Piperacilina + tazobactam basi | Piperacilina + tazobactam generis | Piperacilina + tazobactam kabi | Piperacilina + tazobactam teva | Piperacilina/Tazobactam Orchid | Tazobac</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Moltrazen | Piperacilina + tazobactam eticos | Piperacilina + tazobactam fada pharma | Piperacilina + tazobactam heisecke | Piperacilina + tazobactam imedic | Piperacilina + tazobactam nortelab | Piperacilina - tazobactam pharmavial | Piperacilina tazobactam richet | Tazonam</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aurotaz | Prizma | Tazocin | Yanoven</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bactacin | Perasin | Zopecilin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Pilactam | Piperacillin + Tazobactam | Piperacillin + tazobactam alkem | Piperacillin + Tazobactam Kabi | Piperacillin + tazobactam teva | Piperacillin+tazobactam | Piperacillin+tazobactam alkem | Piperacillin+tazobactam kabi | Santaz | Tacillin j | Tazocin | Tazrobida</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">PIPERACILLIN TAZOPACTAM SANDOZ | Prizma | Tazocin | Tazocin + edta | Tazorax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/Tazobactam Actavis | Piperacillin/Tazobactam FarmaPlus | Piperacillin/Tazobactam fresenius Kabi | Piperacillin/Tazobactam Hospira | Piperacillin/Tazobactam Reig Jofre | Piperacillin/tazobactam sandoz | Piperacillin/Tazobactam Stragen</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin/tazobactam kabi | Tazocin | Tazpen | Tazrobida</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Piperacilin/Tazobactam | Piperacilin/tazobaktam kabi | Piperacilin/tazobaktam mylan | Piperacillin/Tazobactam Pharmaswiss | Piperacillin/Tazobactam Teva | Tazocin | Tazonam</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Piperacilin Comp | Piperacillin/tazobactam | Piperacillin/Tazobactam Actavis | Piperacillin/tazobactam sandoz | Piperacillin/Tazobactam Teva | Tazocin | Tebranic</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lintaz | Peratam | Piperacillin and tazobactam | Pipzo | Tazilsun | Tazocin | Tazrobida | Tebranic</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Prizma | Tazobact | Tazocilline | Tazorex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Avitaz | Tazeracin | Tazocin | Tazoject | Tazoper | Tipraxin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Betamycin | Co Tazo | Jeita | Pipetazo | Pisutam | Tapimycin | Taro | Tazocin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aurotaz r | Piperacilline tazobactam | Refex | Zopercin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Piptazo | Pipzo | Pisa | Tazobak</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Pipebac | Piperazan | Pipertazo | Suldiazan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Tazact | Tazilim | Tazobax | Tazopril | Zibactam | Zitax</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Tazopelin | Vitazovilin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Caplin | Curitaz | Litha piperacil co | Piperacillin/tazobactam fresenius | Pirabax | Razobin | Tazobax | Tazocin | Tazogen</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Curitaz</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Tazocin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31487382">
<a name="31487382"></a>Abbott L, Plummer A, Hoo ZH, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD006682. doi:10.1002/14651858.CD006682.pub6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31487382/pubmed" id="31487382" target="_blank">31487382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious diseases group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and sepsis working group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper.<i> Intensive Care Med.</i> 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26754759">
<a name="26754759"></a>Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. <i>Intensive Care Med</i>. 2016;42(10):1535-1545. doi:10.1007/s00134-015-4188-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26754759/pubmed" id="26754759" target="_blank">26754759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6491103">
<a name="6491103"></a>Adkinson NF Jr. Risk factors for drug allergy. <i>J Allergy Clin Immunol</i>. 1984;74(4 Pt 2):567‐572. doi:10.1016/0091-6749(84)90108-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/6491103/pubmed" id="6491103" target="_blank">6491103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al; and The National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26702922">
<a name="26702922"></a>Alobaid AS, Brinkmann A, Frey OR, et al. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients? <i>J Antimicrob Chemother</i>. 2016;71(3):696-702. doi:10.1093/jac/dkv412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26702922/pubmed" id="26702922" target="_blank">26702922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28052849">
<a name="28052849"></a>Alobaid AS, Wallis SC, Jarrett P, et al. Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients. <i>Antimicrob Agents Chemother</i>. 2017;61(3):e01276-16. doi:10.1128/AAC.01276-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28052849/pubmed" id="28052849" target="_blank">28052849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32910809">
<a name="32910809"></a>Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. <i>J Antimicrob Chemother.</i> 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/32910809/pubmed" id="32910809" target="_blank">32910809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29863943">
<a name="29863943"></a>Alzahrani M, Alrumaih I, Alhamad F, Abdel Warith A. Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature. <i>Platelets</i>. 2018;29(6):628‐631. doi:10.1080/09537104.2018.1468025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29863943/pubmed" id="29863943" target="_blank">29863943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742677">
<a name="28742677"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion No. 712: intrapartum management of intraamniotic infection. <i>Obstet Gynecol</i>. 2017;130(2):e95-e101. doi:10.1097/AOG.0000000000002236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28742677/pubmed" id="28742677" target="_blank">28742677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23845922">
<a name="23845922"></a>Arnold DM, Nazi I, Warkentin TE, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. <i>Transfus Med Rev</i>. 2013;27(3):137‐145. doi:10.1016/j.tmrv.2013.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23845922/pubmed" id="23845922" target="_blank">23845922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007:61, 153.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15647409">
<a name="15647409"></a>Arzuaga A, Maynar J, Gascón AR, et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. <i>J Clin Pharmacol</i>. 2005;45(2):168–176. doi:10.1177/0091270004269796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/15647409/pubmed" id="15647409" target="_blank">15647409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23908259">
<a name="23908259"></a>Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, et al. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. <i>J Antimicrob Chemother</i>. 2014;69(1):180-189. doi:10.1093/jac/dkt304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23908259/pubmed" id="23908259" target="_blank">23908259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28640009">
<a name="28640009"></a>Avedissian SN, Bradley E, Zhang D, et al. Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients. <i>Pediatr Crit Care Med</i>. 2017;18(9):e388-e394. doi:10.1097/PCC.0000000000001228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28640009/pubmed" id="28640009" target="_blank">28640009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019a">
<a name="Baddour.2019a"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019b">
<a name="Baddour.2019b"></a>Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29649586">
<a name="29649586"></a>Balcı C, Uzun Ö, Arıcı M, Hayran SA, Yüce D, Ünal S. Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern? <i>Int J Antimicrob Agents</i>. 2018;52(2):180‐184. doi:10.1016/j.ijantimicag.2018.03.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29649586/pubmed" id="29649586" target="_blank">29649586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27080992">
<a name="27080992"></a>Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. <i>Clin Infect Dis</i>. 2016;62(10):e51‐e77. doi:10.1093/cid/ciw118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27080992/pubmed" id="27080992" target="_blank">27080992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.2019">
<a name="Barshak.2019"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29862466">
<a name="29862466"></a>Béranger A, Benaboud S, Urien S, et al. Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance. <i>Clin Pharmacokinet</i>. 2019;58(2):223-233. doi:10.1007/s40262-018-0682-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29862466/pubmed" id="29862466" target="_blank">29862466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24908632">
<a name="24908632"></a>Bollotte A, Vial T, Bricca P, Bernard C, Broussolle C, Sève P. Les anémies hémolytiques immunologiques médicamenteuses: étude rétrospective de 10 observations [Drug-induced immune hemolytic anemia: a retrospective study of 10 cases] [in French]. <i>Rev Med Interne</i>. 2014;35(12):779‐789. doi:10.1016/j.revmed.2014.05.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24908632/pubmed" id="24908632" target="_blank">24908632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26260647">
<a name="26260647"></a>Bose S, Wurm E, Popovich MJ, Silver BJ. Drug-induced immune-mediated thrombocytopenia in the intensive care unit. <i>J Clin Anesth</i>. 2015;27(7):602‐605. doi:10.1016/j.jclinane.2015.06.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26260647/pubmed" id="26260647" target="_blank">26260647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9481541">
<a name="9481541"></a>Bourget P, Sertin A, Lesne-Hulin A, et al. Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination. <i>Eur J Obstet Gynecol Reprod Biol.</i> 1998;76(1):21-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/9481541/pubmed" id="9481541" target="_blank">9481541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29555607">
<a name="29555607"></a>Bower M, Borders C, Schnure A, Groysman L, Tran MH. Platelet dysfunction and intracerebral hemorrhage in a patient treated with empiric piperacillin-tazobactam in the neurocritical care unit. <i>World Neurosurg</i>. 2018;114:204‐210. doi:10.1016/j.wneu.2018.03.080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29555607/pubmed" id="29555607" target="_blank">29555607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27670947">
<a name="27670947"></a>Boyce K, Brar H, Stabler SN. Piperacillin/tazobactam-induced immune-mediated thrombocytopenia in the intensive care unit. <i>J Clin Pharm Ther</i>. 2016;41(6):730‐732. doi:10.1111/jcpt.12458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27670947/pubmed" id="27670947" target="_blank">27670947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2022">
<a name="Bradley.2022"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Association of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24503131">
<a name="24503131"></a>Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by <i>Clostridium difficile</i>. <i>Gastroenterology</i>. 2014;146(6):1547‐1553. doi:10.1053/j.gastro.2014.01.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24503131/pubmed" id="24503131" target="_blank">24503131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326‐2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7514977">
<a name="7514977"></a>Bryson HM and Brogden RN, “Piperacillin/Tazobactam. A Review of its Antibacterial Activity, Pharmacokinetic Properties, and Therapeutic Potential,” <i>Drugs</i>, 1994, 47(3):506-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/7514977/pubmed" id="7514977" target="_blank">7514977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30172962">
<a name="30172962"></a>Buckley MS, Hartsock NC, Berry AJ, et al. Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit. <i>J Crit Care</i>. 2018;48:32‐38. doi:10.1016/j.jcrc.2018.08.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/30172962/pubmed" id="30172962" target="_blank">30172962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24855041">
<a name="24855041"></a>Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. <i>Pharmacotherapy</i>. 2014;34(7):670‐676. doi:10.1002/phar.1442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24855041/pubmed" id="24855041" target="_blank">24855041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35390523">
<a name="35390523"></a>Butragueño-Laiseca L, Marco-Ariño N, Troconiz IF, et al. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy. <i>Clin Microbiol Infect</i>. 2022;28(9):1287.e9-1287.e15. doi:10.1016/j.cmi.2022.03.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/35390523/pubmed" id="35390523" target="_blank">35390523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23869050">
<a name="23869050"></a>Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. <i>J Antimicrob Chemother</i>. 2014;69(1):176-179. doi: 10.1093/jac/dkt300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23869050/pubmed" id="23869050" target="_blank">23869050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25668894">
<a name="25668894"></a>Cabañas R, Calderon O, Ramirez E, et al. Piperacillin-induced DRESS: distinguishing features observed in a clinical and allergy study of 8 patients. <i>J Investig Allergol Clin Immunol</i>. 2014;24(6):425‐430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25668894/pubmed" id="25668894" target="_blank">25668894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30172963">
<a name="30172963"></a>Carrié C, Legeron R, Petit L, et al. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion. <i>J Crit Care</i>. 2018;48:66-71. doi:10.1016/j.jcrc.2018.08.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/30172963/pubmed" id="30172963" target="_blank">30172963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33444815">
<a name="33444815"></a>Casimir-Brown RS, Kennard L, Kayode OS, et al. Piperacillin-tazobactam hypersensitivity: a large, multicenter analysis. <i>J Allergy Clin Immunol Pract</i>. 2021;S2213-2198(21)00041-6. doi:10.1016/j.jaip.2020.12.051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/33444815/pubmed" id="33444815" target="_blank">33444815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Center for Disease Control and Prevention (CDC). <i>Clostridioides difficile</i> (<i>C. diff</i>). Center for Disease Control and Prevention website. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23228881">
<a name="23228881"></a>Cheatham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. <i>Int J Antimicrob Agents</i>. 2013;41(1):52-56. doi:10.1016/j.ijantimicag.2012.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23228881/pubmed" id="23228881" target="_blank">23228881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27073426">
<a name="27073426"></a>Chen H, Fan Z, Guo F, et al. Tazobactam and piperacillin-induced thrombocytopenia: A case report. <i>Exp Ther Med</i>. 2016;11(4):1223‐1226. doi:10.3892/etm.2016.3062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27073426/pubmed" id="27073426" target="_blank">27073426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27644691">
<a name="27644691"></a>Chen Y, Lu J, Dong M, et al. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants. <i>Eur J Clin Pharmacol</i>. 2016a;72(12):1479-1488. doi:10.1007/s00228-016-2131-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27644691/pubmed" id="27644691" target="_blank">27644691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34029707">
<a name="34029707"></a>Chongcharoenyanon T, Wacharachaisurapol N, Anugulruengkitt S, et al. Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in paediatric patients. <i>Int J Infect Dis</i>. 2021;108:102-108. doi:10.1016/j.ijid.2021.05.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/34029707/pubmed" id="34029707" target="_blank">34029707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29190320">
<a name="29190320"></a>Chotiprasitsakul D, Han JH, Cosgrove SE, et al; Antibacterial Resistance Leadership Group. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. <i>Clin Infect Dis</i>. 2018;66(2):172-177. doi: 10.1093/cid/cix767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29190320/pubmed" id="29190320" target="_blank">29190320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32040830">
<a name="32040830"></a>Ciarambino T, Giannico OV, Campanile A, et al. Acute kidney injury and vancomycin/piperacillin/tazobactam in adult patients: a systematic review. <i>Intern Emerg Med</i>. 2020;15(2):327‐331. doi:10.1007/s11739-020-02287-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/32040830/pubmed" id="32040830" target="_blank">32040830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29112080">
<a name="29112080"></a>Cies JJ, Moore WS 2nd, Enache A, Chopra A. β-lactam therapeutic drug management in the PICU. <i>Crit Care Med</i>. 2018;46(2):272-279. doi:10.1097/CCM.0000000000002817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29112080/pubmed" id="29112080" target="_blank">29112080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23907263">
<a name="23907263"></a>Cies JJ, Shankar V, Schlichting C, Kuti JL. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. <i>Pediatr Infect Dis J</i>. 2014;33(2):168-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23907263/pubmed" id="23907263" target="_blank">23907263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24614369">
<a name="24614369"></a>Cohen-Wolkowiez M, Watt KM, Zhou C, et al. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. <i>Antimicrob Agents Chemother</i>. 2014;58(5):2856-2865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24614369/pubmed" id="24614369" target="_blank">24614369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141‐1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32042284">
<a name="32042284"></a>Copaescu AM, Bouffard D, Masse MS. Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: case presentation and literature review. <i>Allergy Asthma Clin Immunol</i>. 2020;16:9. Published 2020 Feb 4. doi:10.1186/s13223-020-0407-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/32042284/pubmed" id="32042284" target="_blank">32042284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14979482">
<a name="14979482"></a>Cornely OA, Wicke T, Seifert H, et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. <i>Int J Hematol</i>. 2004;79(1):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/14979482/pubmed" id="14979482" target="_blank">14979482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19422028">
<a name="19422028"></a>Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. <i>Pediatr Blood Cancer</i>. 2009;53(3):379-385. doi:10.1002/pbc.22051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19422028/pubmed" id="19422028" target="_blank">19422028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis.</i> 1998;26(1):1-10. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>Clin Microbiol Newsletter</i>. 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol</i>. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Darwiche.2017">
<a name="Darwiche.2017"></a>Darwiche D, Iskandar K, Azar R, Hallit R, Hallit S. Piperacillin-Tazobactam-induced neutropenia: A case report. <i>J Medical Case</i>. 2017;8(9):280-282.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36422708">
<a name="36422708"></a>Debray A, Callot D, Hirt D, et al. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study. <i>Eur J Pediatr</i>. 2023;182(3):965-973. doi:10.1007/s00431-022-04716-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/36422708/pubmed" id="36422708" target="_blank">36422708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2324971">
<a name="2324971"></a>Debruyne D, Ryckelynck JP, Hurault De Ligny B, Moulin M. Pharmacokinetics of piperacillin in patients on peritoneal dialysis with and without peritonitis. <i>J Pharm Sci</i>. 1990;79(2):99-102. doi:10.1002/jps.2600790204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/2324971/pubmed" id="2324971" target="_blank">2324971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629023">
<a name="23629023"></a>Delvallée M, Mazingue F, Abouchahla W, et al. Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia. <i>Pediatr Infect Dis J</i>. 2013;32(9):962-964. doi:10.1097/INF.0b013e318298dfb8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23629023/pubmed" id="23629023" target="_blank">23629023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951‐1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30374606">
<a name="30374606"></a>Dhont E, Van Der Heggen T, De Jaeger A, Vande Walle J, De Paepe P, De Cock PA. Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? <i>Pediatr Nephrol</i>. 2020;35(1):25-39. doi:10.1007/s00467-018-4120-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/30374606/pubmed" id="30374606" target="_blank">30374606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21603168">
<a name="21603168"></a>Díaz Angulo S, Szram J, Welch J, Cannon J, Cullinan P. Occupational asthma in antibiotic manufacturing workers: case reports and systematic review. <i>J Allergy (Cairo)</i>. 2011;2011:365683. doi:10.1155/2011/365683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/21603168/pubmed" id="21603168" target="_blank">21603168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Egan.1">
<a name="Egan.1"></a>Egan ME, Schechter MS, Voynow JA. Cystic fibrosis. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 432.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31428326">
<a name="31428326"></a>ElSalem S, Elawad S, Ahmed A, AlSaadi M, AlHail M. A case of probable piperacillin/tazobactam-induced bone marrow suppression in a pregnant woman. <i>Eur J Hosp Pharm</i>. 2019;26(3):170‐172. doi:10.1136/ejhpharm-2017-001243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31428326/pubmed" id="31428326" target="_blank">31428326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.<i> Intensive Care Med.</i> 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.2019">
<a name="File.2019"></a>File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19729669">
<a name="19729669"></a>Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. <i>Am J Respir Crit Care Med</i>. 2009;180(9):802-808. doi: 10.1164/rccm.200812-1845PP.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19729669/pubmed" id="19729669" target="_blank">19729669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33480024">
<a name="33480024"></a>Fratoni AJ, Nicolau DP, Kuti JL. A guide to therapeutic drug monitoring of β-lactam antibiotics. <i>Pharmacotherapy</i>. 2021;41(2):220-233. doi:10.1002/phar.2505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/33480024/pubmed" id="33480024" target="_blank">33480024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93. doi: 10.1093/cid/cir073.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30552984">
<a name="30552984"></a>García-Moguel I, Bobolea I, Diéguez Pastor MC, López-Arranz Monge G, Barranco Jimenez R. Acute eosinophilic pneumonia due to piperacillin/tazobactam. <i>Ann Allergy Asthma Immunol</i>. 2019;122(3):334‐336. doi:10.1016/j.anai.2018.12.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/30552984/pubmed" id="30552984" target="_blank">30552984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29383926">
<a name="29383926"></a>Gaspar-Marques J, Finelli E, Martins PC, Prates S, Leiria-Pinto P. Piperacillin-tazobactam anaphylaxis: a rare cause of occupational disease. <i>Eur Ann Allergy Clin Immunol</i>. 2018;50(2):89‐91. doi:10.23822/EurAnnACI.1764-1489.29<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29383926/pubmed" id="29383926" target="_blank">29383926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8645807">
<a name="8645807"></a>Gerber L, Wing EJ. Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. <i>Clin Infect Dis</i>. 1995;21(4):1047‐1048. doi:10.1093/clinids/21.4.1047-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/8645807/pubmed" id="8645807" target="_blank">8645807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090866">
<a name="29090866"></a>Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. <i>J Hepatobiliary Pancreat Sci</i>. 2018;25(1):3-16. doi: 10.1002/jhbp.518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29090866/pubmed" id="29090866" target="_blank">29090866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34469706">
<a name="34469706"></a>Goss CH, Heltshe SL, West NE, et al; STOP2 Investigators. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. <i>Am J Respir Crit Care Med</i>. 2021;204(11):1295-1305. doi:10.1164/rccm.202102-0461OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/34469706/pubmed" id="34469706" target="_blank">34469706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grandis.2018">
<a name="Grandis.2018"></a>Grandis JR. Malignant (necrotizing) external otitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21501212">
<a name="21501212"></a>Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. <i>Br J Clin Pharmacol</i>. 2011;72(3):381‐393. doi:10.1111/j.1365-2125.2011.03991.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/21501212/pubmed" id="21501212" target="_blank">21501212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care</i>. 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021">
<a name="Hooton.2021"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21896561">
<a name="21896561"></a>Gyssens IC, Dryden M, Kujath P, et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. <i>J Antimicrob Chemother</i>. 2011;66(11):2632-2642. doi: 10.1093/jac/dkr344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/21896561/pubmed" id="21896561" target="_blank">21896561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26952639">
<a name="26952639"></a>Hammond DA, Smith MN, Painter JT, Meena NK, Lusardi K. Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: A retrospective cohort study. <i>Pharmacotherapy</i>. 2016;36(5):463‐471. doi:10.1002/phar.1738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26952639/pubmed" id="26952639" target="_blank">26952639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20636224">
<a name="20636224"></a>Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. <i>Expert Opin Drug Metab Toxicol</i>. 2010;6(8):1017-1031. doi:10.1517/17425255.2010.506187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/20636224/pubmed" id="20636224" target="_blank">20636224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32470139">
<a name="32470139"></a>Hays WB, Flack T. Safety and tolerability of i.v. push piperacillin/tazobactam within an emergency department. <i>Am J Health Syst Pharm</i>. 2020;77(13):1051-1053. doi:10.1093/ajhp/zxaa114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/32470139/pubmed" id="32470139" target="_blank">32470139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23826789">
<a name="23826789"></a>He ZF, Wu XA, Wang YP. Severe bone marrow suppression and hepatic dysfunction caused by piperacillin/tazobactam. <i>Scand J Infect Dis</i>. 2013;45(11):885‐887. doi:10.3109/00365548.2013.805426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23826789/pubmed" id="23826789" target="_blank">23826789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19209277">
<a name="19209277"></a>Hedge DD, Strain JD, Heins JR, Farver DK. New advances in the treatment of <i>Clostridium difficile</i> infection (CDI). <i>Ther Clin Risk Manag</i>. 2008;4(5):949‐964. doi:10.2147/tcrm.s3145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19209277/pubmed" id="19209277" target="_blank">19209277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy. </i>2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742‐748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24956136">
<a name="24956136"></a>Hites M, Taccone FS, Wolff F, et al. Broad-spectrum β-lactams in obese non-critically ill patients. <i>Nutr Diabetes</i>. 2014;4(6):e119. doi:10.1038/nutd.2014.15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24956136/pubmed" id="24956136" target="_blank">24956136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33911483">
<a name="33911483"></a>Ho YH, Chiu YW, Liu HN. Piperacillin-tazobactam-induced linear IgA bullous dermatosis supported by a T-cell activation assay. <i>Ann Dermatol</i>. 2018;30(5):588-591. doi:10.5021/ad.2018.30.5.588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/33911483/pubmed" id="33911483" target="_blank">33911483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19499182">
<a name="19499182"></a>Huang WT, Hsu YJ, Chu PL, Lin SH. Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure. <i>Infection</i>. 2009;37(4):374‐376. doi:10.1007/s15010-009-8373-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19499182/pubmed" id="19499182" target="_blank">19499182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29091190">
<a name="29091190"></a>Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. <i>J Antimicrob Chemother.</i> 2017;72(10):2891-2897. doi:10.1093/jac/dkx209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29091190/pubmed" id="29091190" target="_blank">29091190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25881872">
<a name="25881872"></a>Jamal JA, Roberts DM, Udy AA, et al. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. <i>Int J Antimicrob Agents</i>. 2015;46(1):39-44. doi:10.1016/j.ijantimicag.2015.02.014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25881872/pubmed" id="25881872" target="_blank">25881872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24674926">
<a name="24674926"></a>Jamal JA, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. <i>Crit Care Med</i>. 2014;42(7):1640-1650. doi:10.1097/CCM.0000000000000317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24674926/pubmed" id="24674926" target="_blank">24674926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22411933">
<a name="22411933"></a>Jensen JU, Hein L, Lundgren B, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. <i>BMJ Open</i>. 2012;2(2):e000635. Published 2012 Mar 11. doi:10.1136/bmjopen-2011-000635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/22411933/pubmed" id="22411933" target="_blank">22411933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29298155">
<a name="29298155"></a>Johnson JR, Russo TA. Acute pyelonephritis in adults [published correction appears in <i>N Engl J Med.</i> 2018;378(11):1069]. <i>N Engl J Med.</i> 2018;378(1):48-59. Review.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29298155/pubmed" id="29298155" target="_blank">29298155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31210955">
<a name="31210955"></a>Kadomura S, Takekuma Y, Sato Y, et al. Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study. <i>J Pharm Health Care Sci</i>. 2019;5:13. Published 2019 Jun 12. doi:10.1186/s40780-019-0142-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31210955/pubmed" id="31210955" target="_blank">31210955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.1">
<a name="Kanj.1"></a>Kanj SS, Sexton DJ. Pseudomonas aeruginosa bacteremia and endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 8, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.3">
<a name="Kanj.3"></a>Kanj SS. Principles of antimicrobial therapy of Pseudomonas aeruginosa infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 8, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.4">
<a name="Kanj.4"></a>Kanj SS, Sexton DJ. Pseudomonas aeruginosa skin and soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 8, 2023c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29730948">
<a name="29730948"></a>Kanji S, Roberts JA, Xie J, et al. Piperacillin population pharmacokinetics in critically ill adults during sustained low-efficiency dialysis. <i>Ann Pharmacother</i>. 2018;52(10):965-973. doi:10.1177/1060028018773771<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29730948/pubmed" id="29730948" target="_blank">29730948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23855313">
<a name="23855313"></a>Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. <i>Br J Dermatol</i>. 2013;169(5):1071‐1080. doi:10.1111/bjd.12501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/23855313/pubmed" id="23855313" target="_blank">23855313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27067325">
<a name="27067325"></a>Karino S, Kaye KS, Navalkele B, et al. Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin-tazobactam: Opportunities for antimicrobial stewardship. <i>Antimicrob Agents Chemother</i>. 2016;60(6):3743‐3750. doi:10.1128/AAC.03011-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27067325/pubmed" id="27067325" target="_blank">27067325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan2005">
<a name="Khan2005"></a>Khan FY. Severe neutropenia secondary to piperacillin/tazobactam therapy. <i>Indian J Pharmacol</i> 2005;37:192-3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26476979">
<a name="26476979"></a>Kim T, Kandiah S, Patel M, et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. <i>BMC Res Notes</i>. 2015;8:579. doi:10.1186/s13104-015-1518-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26476979/pubmed" id="26476979" target="_blank">26476979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21532862">
<a name="21532862"></a>Kim JE, Kim SH, Kim JH, et al. A case of piperacillin-induced occupational anaphylaxis: detection of serum IgE to piperacillin-HSA conjugate. <i>J Korean Med Sci</i>. 2011;26(5):682‐685. doi:10.3346/jkms.2011.26.5.682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/21532862/pubmed" id="21532862" target="_blank">21532862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17963458">
<a name="17963458"></a>Kim A, Sutherland CA, Kuti JL, et al. Optimal Dosing of Piperacillin-Tazobactam for the Treatment of <i>Pseudomonas aeruginosa</i> Infections: Prolonged or Continuous infusion. <i>Pharmacother.</i> 2007;27(11):1490-1497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/17963458/pubmed" id="17963458" target="_blank">17963458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28638304">
<a name="28638304"></a>Knoderer CA, Karmire LC, Andricopulos KL, Nichols KR. Extended infusion of piperacillin/tazobactam in children. <i>J Pediatr Pharmacol Ther</i>. 2017;22(3):212-217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28638304/pubmed" id="28638304" target="_blank">28638304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33170417">
<a name="33170417"></a>Kobayashi R, Sano H, Matsushima S, et al. Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day. <i>Int J Hematol</i>. 2021;113(3):430-435. doi:10.1007/s12185-020-03031-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/33170417/pubmed" id="33170417" target="_blank">33170417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27434982">
<a name="27434982"></a>Kraleti S, Khatri N, Jarrett D. Piperacillin-tazobactam induced interstitial nephritis, hepatitis and serum sickness-like illness. <i>J Ark Med Soc</i>. 2016;112(14):278-280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27434982/pubmed" id="27434982" target="_blank">27434982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12791166">
<a name="12791166"></a>Kumar A, Choudhuri G, Aggarwal R. Piperacillin induced bone marrow suppression: a case report. <i>BMC Clin Pharmacol</i>. 2003;3:2. doi:10.1186/1472-6904-3-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/12791166/pubmed" id="12791166" target="_blank">12791166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34132703">
<a name="34132703"></a>Lee J, Garvey EM, Bundrant N, et al. IMPPACT (Intravenous Monotherapy for Postoperative Perforated Appendicitis in Children Trial): randomized clinical trial of monotherapy versus multi-drug antibiotic therapy. <i>Ann Surg</i>. 2021;274(3):406-410. doi:10.1097/SLA.0000000000005006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/34132703/pubmed" id="34132703" target="_blank">34132703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22505967">
<a name="22505967"></a>Lee KW, Chow KM, Chan NP, Lo AO, Szeto CC. Piperacillin/tazobactam Induced Myelosuppression. <i>J Clin Med Res</i>. 2009;1(1):53‐55. doi:10.4021/jocmr2009.03.1227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/22505967/pubmed" id="22505967" target="_blank">22505967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3488418">
<a name="3488418"></a>Lee M, Stobnicki M, Sharifi R. Hemorrhagic complications of piperacillin therapy. <i>J Urol</i>. 1986;136(2):454‐455. doi:10.1016/s0022-5347(17)44906-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/3488418/pubmed" id="3488418" target="_blank">3488418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28459614">
<a name="28459614"></a>Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. <i>J Clin Oncol</i>. 2017;35(18):2082-2094. doi:10.1200/JCO.2016.71.7017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28459614/pubmed" id="28459614" target="_blank">28459614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36689694">
<a name="36689694"></a>Lehrnbecher T, Robinson PD, Ammann RA. Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update. <i>J Clin Oncol</i>. 2023;41(9):1774-1785. doi:10.1200/JCO.22.02224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/36689694/pubmed" id="36689694" target="_blank">36689694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9145893">
<a name="9145893"></a>Li RC, Lee SW. Postantibiotic effect assessments for antibiotics exhibiting a wide range of bactericidal activities by using a modified total-cell-counting method. <i>Antimicrob Agents Chemother.</i> 1997;41(5):1170-1172. doi:10.1128/AAC.41.5.1170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/9145893/pubmed" id="9145893" target="_blank">9145893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17496739">
<a name="17496739"></a>Lin CS, Cheng CJ, Chou CH, Lin SH. Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. <i>Am J Med Sci</i>. 2007;333(3):181‐184. doi:10.1097/MAJ.0b013e31803195e7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/17496739/pubmed" id="17496739" target="_blank">17496739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24599767">
<a name="24599767"></a>Lin YF, Yang CH, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. <i>Clin Infect Dis</i>. 2014;58(10):1377‐1385. doi:10.1093/cid/ciu126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24599767/pubmed" id="24599767" target="_blank">24599767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548459">
<a name="21548459"></a>Linares T, Fernández A, Soto MT, Escudero E, Gacías L. Drug fever caused by piperacillin-tazobactam. <i>J Investig Allergol Clin Immunol</i>. 2011;21(3):250‐251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/21548459/pubmed" id="21548459" target="_blank">21548459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22722588">
<a name="22722588"></a>Liu TJ, Lam JP. Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis. <i>Am J Health Syst Pharm</i>. 2012;69(13):1109. doi:10.2146/ajhp120068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/22722588/pubmed" id="22722588" target="_blank">22722588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17205441">
<a name="17205441"></a>Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for <i>Pseudomonas aeruginosa</i> infection: clinical implications of an extended-infusion dosing strategy. <i>Clin Infect Dis</i>. 2007;44(3):357-363. doi: 10.1086/510590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/17205441/pubmed" id="17205441" target="_blank">17205441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16945055">
<a name="16945055"></a>Lodise TP, Lomaestro BM, Drusano GL; Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i>. 2006;26(9):1320-1332. doi:10.1592/phco.26.9.1320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/16945055/pubmed" id="16945055" target="_blank">16945055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29088001">
<a name="29088001"></a>Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: A systematic review and meta-analysis. <i>Crit Care Med</i>. 2018;46(1):12‐20. doi:10.1097/CCM.0000000000002769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29088001/pubmed" id="29088001" target="_blank">29088001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34796702">
<a name="34796702"></a>Maarbjerg SF, Thorsted A, Friberg LE, et al. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever. <i>Cancer Rep (Hoboken)</i>. 2022;5(10):e1585. doi:10.1002/cnr2.1585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/34796702/pubmed" id="34796702" target="_blank">34796702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30740885">
<a name="30740885"></a>Maarbjerg SF, Thorsted A, Kristoffersson A, et al. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: can we optimize our dosing strategy? <i>Pediatr Blood Cancer</i>. 2019;66(6):e27654. doi:10.1002/pbc.27654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/30740885/pubmed" id="30740885" target="_blank">30740885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24359838">
<a name="24359838"></a>MacVane SH, Kuti JL, Nicolau DP. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation. <i>Int J Antimicrob Agents</i>. 2014;43(2):105-113. doi: 10.1016/j.ijantimicag.2013.10.021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24359838/pubmed" id="24359838" target="_blank">24359838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22778457">
<a name="22778457"></a>Macwilliam JL, Mistry R, Floyd MS Jr, Baird AD. Piperacillin/tazobactam induced thrombocytopaenia--a delayed response. <i>BMJ Case Rep</i>. 2012;2012:bcr0320125981. doi:10.1136/bcr.03.2012.5981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/22778457/pubmed" id="22778457" target="_blank">22778457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11714046">
<a name="11714046"></a>Maltezou HC, Nikolaidis P, Lebesii E, Dimitriou L, Androulakakis E, Kafetzis DA. Piperacillin/tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. <i>Eur J Clin Microbiol Infect Dis</i>. 2001;20(9):643-646. doi:10.1007/s100960100581<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/11714046/pubmed" id="11714046" target="_blank">11714046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11216560">
<a name="11216560"></a>Manley HJ, Bailie GR, Frye R, McGoldrick MD. Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis patients. <i>Perit Dial Int</i>. 2000;20(6):686-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/11216560/pubmed" id="11216560" target="_blank">11216560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society (SIS) revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1‐e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27784223">
<a name="27784223"></a>Mellen CK, Ryba JE, Rindone JP. Does piperacillin-tazobactam increase the risk of nephrotoxicity when used with vancomycin: a meta-analysis of observational trials. <i>Curr Drug Saf</i>. 2017;12(1):62-66. doi: 10.2174/1574886311666161024164859.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27784223/pubmed" id="27784223" target="_blank">27784223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28869666">
<a name="28869666"></a>Meng L, Mui E, Holubar MK, Deresinski SC. Comprehensive guidance for antibiotic dosing in obese adults. <i>Pharmacotherapy</i>. 2017;37(11):1415-1431. doi:10.1002/phar.2023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28869666/pubmed" id="28869666" target="_blank">28869666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published correction appears in: <i>Clin Infect Dis</i>. 2010;50(7):1079 (dosage error in article text); <i>Clin Infect Dis</i>. 2010;50(3):457]. <i>Clin Infect Dis</i>. 2009;49(1):1-45. doi: 10.1086/599376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624028">
<a name="29624028"></a>Mesini A, Loy A, Losurdo G, et al. Uncommon occurrence of high piperacillin-tazobactam and meropenem plasma concentrations and concomitant absence of neurotoxicity in pediatrics. <i>Minerva Anestesiol</i>. 2018;84(9):1111-1112. doi:10.23736/S0375-9393.18.12600-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29624028/pubmed" id="29624028" target="_blank">29624028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Respir Crit Care Med</i>. 2019;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25623506">
<a name="25623506"></a>Mirakian R, Leech SC, Krishna MT, et al. Management of allergy to penicillins and other beta-lactams. <i>Clin Exp Allergy</i>. 2015;45(2):300‐327. doi:10.1111/cea.12468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25623506/pubmed" id="25623506" target="_blank">25623506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29798969">
<a name="29798969"></a>Miyabayashi H, Kumaki S, Sato A, et al. Onset of hemophagocytic lymphohistiocytosis during piperacillin-tazobactam therapy in three children with acute focal bacterial nephritis. <i>Tohoku J Exp Med</i>. 2018;245(1):55-59. doi:10.1620/tjem.245.55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29798969/pubmed" id="29798969" target="_blank">29798969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.2019a">
<a name="Moehring.2019a"></a>Moehring R. Prolonged infusions of beta-lactam antibiotics. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 8, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.2019b">
<a name="Moehring.2019b"></a>Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 8, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30741072">
<a name="30741072"></a>Molina KC, Barletta JF, Hall ST, Yazdani C, Huang V. The risk of acute kidney injury in critically ill patients receiving concomitant vancomycin with piperacillin-tazobactam or cefepime [published online ahead of print, 2019 Feb 10]. <i>J Intensive Care Med</i>. 2019;885066619828290. doi:10.1177/0885066619828290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/30741072/pubmed" id="30741072" target="_blank">30741072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3975759">
<a name="3975759"></a>Moore M, McNamara TR, Johnson J. Elevated bleeding time and epistaxis associated with piperacillin therapy. <i>South Med J</i>. 1985;78(3):363. doi:10.1097/00007611-198503000-00037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/3975759/pubmed" id="3975759" target="_blank">3975759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35359889">
<a name="35359889"></a>Morales Junior R, Pereira GO, Tiguman GMB, et al. Beta-lactams therapeutic monitoring in septic children-what target are we aiming for? A scoping review. <i>Front Pediatr</i>. 2022;10:777854. doi:10.3389/fped.2022.777854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/35359889/pubmed" id="35359889" target="_blank">35359889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017a;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017b;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29442542">
<a name="29442542"></a>Mullins BP, Kramer CJ, Bartel BJ, Catlin JS, Gilder RE. Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin/tazobactam: A prospective, multicenter study. <i>Ann Pharmacother</i>. 2018;52(7):639‐644. doi:10.1177/1060028018757497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29442542/pubmed" id="29442542" target="_blank">29442542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Mylan-Piperacillin and Tazobactam for Injection [product monograph]. Etobicoke, Ontario, Canada: Mylan Pharmaceuticals ULC; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27986669">
<a name="27986669"></a>Navalkele B, Pogue JM, Karino S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. <i>Clin Infect Dis</i>. 2017;64(2):116‐123. doi:10.1093/cid/ciw709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27986669/pubmed" id="27986669" target="_blank">27986669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24650475">
<a name="24650475"></a>Nazarey PP, Stylianos S, Velis E, et al. Treatment of suspected acute perforated appendicitis with antibiotics and interval appendectomy. <i>J Pediatr Surg</i>. 2014;49(3):447-450. doi:10.1016/j.jpedsurg.2013.10.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24650475/pubmed" id="24650475" target="_blank">24650475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25098503">
<a name="25098503"></a>Neves PD, Freitas FM, Kojima CA, et al. Piperacillin/tazobactam-induced neurotoxicity in a hemodialysis patient: a case report. <i>Hemodial Int</i>. 2015;19(1):143‐145. doi:10.1111/hdi.12194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25098503/pubmed" id="25098503" target="_blank">25098503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26684560">
<a name="26684560"></a>Nguyen VD, Tourigny JF, Roy R, Brouillette D. Rapid-onset thrombocytopenia following piperacillin-tazobactam reexposure. <i>Pharmacotherapy</i>. 2015;35(12):e326‐e330. doi:10.1002/phar.1675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26684560/pubmed" id="26684560" target="_blank">26684560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26552978">
<a name="26552978"></a>Nichols K, Chung EK, Knoderer CA, et al. Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically ill children. <i>Antimicrob Agents Chemother</i>. 2016a;60(1):522-531.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26552978/pubmed" id="26552978" target="_blank">26552978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26917819">
<a name="26917819"></a>Nichols KR, Israel EN, Thomas CA, Knoderer CA. Optimizing guideline-recommended antibiotic doses for pediatric infective endocarditis. <i>Ann Pharmacother</i>. 2016b;50(5):423-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26917819/pubmed" id="26917819" target="_blank">26917819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34588142">
<a name="34588142"></a>Nicholson TT, Smith A, McKone EF, Gallagher CG. Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: A systematic review. <i>J Cyst Fibros</i>. 2022;21(4):562-573. doi:10.1016/j.jcf.2021.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/34588142/pubmed" id="34588142" target="_blank">34588142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7962988">
<a name="7962988"></a>Nowé P. Piperacillin/tazobactam in complicated urinary tract infections. <i>Intensive Care Med.</i> 1994;20(suppl 3):S39-S42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/7962988/pubmed" id="7962988" target="_blank">7962988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OUHSC.2015">
<a name="OUHSC.2015"></a>OUHSC. Drug-induced thrombocytopenia. University of Oklahoma Health Science Center website. <a href="https://www.ouhsc.edu/platelets/ditp.html" target="_blank">https://www.ouhsc.edu/platelets/ditp.html</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1467132">
<a name="1467132"></a>Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. <i>Br J Clin Pharmacol</i>. 1992;34(5):377‐395. doi:10.1111/j.1365-2125.1992.tb05647.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/1467132/pubmed" id="1467132" target="_blank">1467132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19858253">
<a name="19858253"></a>Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. <i>Antimicrob Agents Chemother.</i> 2010;54(1):460-465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19858253/pubmed" id="19858253" target="_blank">19858253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28784558">
<a name="28784558"></a>Patel S, Levin-Epstein R, Kobashigawa J. Piperacillin-induced thrombocytopenia in a dual heart and kidney transplant patient: A case report. <i>Transplant Proc</i>. 2017;49(7):1672‐1674. doi:10.1016/j.transproceed.2017.02.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28784558/pubmed" id="28784558" target="_blank">28784558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21690532">
<a name="21690532"></a>Peermohamed S, Haber RM. Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: a case report and review of the literature. <i>Arch Dermatol</i>. 2011;147(6):697‐701. doi:10.1001/archdermatol.2011.147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/21690532/pubmed" id="21690532" target="_blank">21690532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.2019">
<a name="Pemberton.2019"></a>Pemberton JH. Acute colonic diverticulitis: Medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30190292">
<a name="30190292"></a>Pettit NN, Nguyen CT, Stahle S, Wong M, Bastow S, Pisano J. Implementing i.v. push administration of piperacillin-tazobactam in response to shortage of small-volume infusion bags. <i>Am J Health Syst Pharm</i>. 2018;75(18):1358-1359. doi:10.2146/ajhp180163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/30190292/pubmed" id="30190292" target="_blank">30190292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Piperacillin and tazobactam [prescribing information]. Lake Zurich, IL: Fresenius Kabi; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.2">
<a name="Hospira.2"></a>Piperacillin and tazobactam [prescribing information]. Lake Forest, IL: Hospira Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Piperacillin sodium and tazobactam sodium [prescribing information]. Lake Forest, IL: Hospira Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.2">
<a name="Mylan.2"></a>Piperacillin and tazobactam [product monograph]. Etobicoke, Ontario, Canada: Mylan Pharmaceuticals ULC; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7924483">
<a name="7924483"></a>Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. <i>Chest</i>. 1994;106(4):1124-1128. doi:10.1378/chest.106.4.1124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/7924483/pubmed" id="7924483" target="_blank">7924483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31496320">
<a name="31496320"></a>Pogue JM, Heil EL. Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world.<i> Expert Opin Pharmacother.</i> 2019;20(17):2053-2057. doi:10.1080/14656566.2019.1663827<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31496320/pubmed" id="31496320" target="_blank">31496320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25463162">
<a name="25463162"></a>Psallidas I, Corcoran JP, Rahman NM. Management of parapneumonic effusions and empyema. <i>Semin Respir Crit Care Med</i>. 2014;35(6):715-722. doi: 10.1055/s-0034-1395503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25463162/pubmed" id="25463162" target="_blank">25463162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36168509">
<a name="36168509"></a>Puckett LM, Newland JG, Girotto JE. Advancing pediatric antimicrobial stewardship: has pharmacodynamic dosing for gram-negative infections taken effect? <i>Antimicrob Steward Healthc Epidemiol</i>. 2021;1(1):e61. doi:10.1017/ash.2021.199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/36168509/pubmed" id="36168509" target="_blank">36168509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28717035">
<a name="28717035"></a>Quinton MC, Bodeau S, Kontar L, et al. Neurotoxic concentration of piperacillin during continuous infusion in critically ill patients. <i>Antimicrob Agents Chemother.</i> 2017;61(9):e00654-17. doi:10.1128/AAC.00654-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28717035/pubmed" id="28717035" target="_blank">28717035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32561442">
<a name="32561442"></a>Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. <i>Chest</i>. 2020;158(5):1896-1911. doi:10.1016/j.chest.2020.05.598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/32561442/pubmed" id="32561442" target="_blank">32561442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17620077">
<a name="17620077"></a>Rank MA, Park MA. Anaphylaxis to piperacillin-tazobactam despite a negative penicillin skin test. <i>Allergy</i>. 2007;62(8):964‐965. doi:10.1111/j.1398-9995.2007.01418.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/17620077/pubmed" id="17620077" target="_blank">17620077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7695268">
<a name="7695268"></a>Reed MD, Goldfarb J, Yamashita T, Lemon E, Blumer JL. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. <i>Antimicrob Agents Chemother.</i> 1994;38(12):2817-2826.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/7695268/pubmed" id="7695268" target="_blank">7695268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10624596">
<a name="10624596"></a>Reichardt P, Handrick W, Linke A, Schille R, Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis. <i>Infection</i>. 1999;27(6):355‐356. doi:10.1007/s150100050042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/10624596/pubmed" id="10624596" target="_blank">10624596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33044871">
<a name="33044871"></a>Ren J, Zheng Y, Du H, et al. Antibiotic-induced black hairy tongue: two case reports and a review of the literature. <i>J Int Med Res</i>. 2020;48(10):300060520961279. doi:10.1177/0300060520961279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/33044871/pubmed" id="33044871" target="_blank">33044871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24867788">
<a name="24867788"></a>Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. <i>Clin Infect Dis</i>. 2014;59(6):905-907. doi:10.1093/cid/ciu402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24867788/pubmed" id="24867788" target="_blank">24867788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36593628">
<a name="36593628"></a>Riggsbee D, Engdahl S, Pettit RS. Evaluation of the safety of piperacillin-tazobactam extended infusion in pediatric cystic fibrosis patients. <i>Pediatr Pulmonol</i>. 2023;58(4):1092-1099. doi:10.1002/ppul.26299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/36593628/pubmed" id="36593628" target="_blank">36593628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337797">
<a name="29337797"></a>Roberts JA. Beta-lactam therapeutic drug monitoring in the critically ill children: big solution for infections in small people? <i>Crit Care Med</i>. 2018;46(2):335-337. doi:10.1097/CCM.0000000000002862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29337797/pubmed" id="29337797" target="_blank">29337797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? <i>Clin Infect Dis</i>. 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24169544">
<a name="24169544"></a>Roehmel JF, Schwarz C, Mehl A, Stock P, Staab D. Hypersensitivity to antibiotics in patients with cystic fibrosis. <i>J Cyst Fibros</i>. 2014;13(2):205-211. doi:10.1016/j.jcf.2013.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24169544/pubmed" id="24169544" target="_blank">24169544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10955713">
<a name="10955713"></a>Romano A, Di Fonso M, Viola M, Adesi FB, Venuti A. Selective hypersensitivity to piperacillin. <i>Allergy</i>. 2000;55(8):787. doi:10.1034/j.1398-9995.2000.00725.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/10955713/pubmed" id="10955713" target="_blank">10955713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19802882">
<a name="19802882"></a>Rousan TA, Aldoss IT, Cowley BD Jr, et al. Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. <i>Am J Hematol</i>. 2010;85(1):71‐74. doi:10.1002/ajh.21536v<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19802882/pubmed" id="19802882" target="_blank">19802882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8982034">
<a name="8982034"></a>Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. <i>Br J Haematol</i>. 1996;95(4):611‐612. doi:10.1046/j.1365-2141.1996.d01-1952.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/8982034/pubmed" id="8982034" target="_blank">8982034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182801">
<a name="28182801"></a>Rutter WC, Burgess DR, Talbert JC, Burgess DS. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis. <i>J Hosp Med</i>. 2017;12(2):77‐82. doi:10.12788/jhm.2684<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28182801/pubmed" id="28182801" target="_blank">28182801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31369116">
<a name="31369116"></a>Rutter WC, Hall RG, Burgess DS. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin. <i>Am J Health Syst Pharm</i>. 2019;76(16):1211‐1217. doi:10.1093/ajhp/zxz120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31369116/pubmed" id="31369116" target="_blank">31369116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31222911">
<a name="31222911"></a>Saffioti C, Mesini A, Barco S, Cangemi G, Bandettini R, Castagnola E. Piperacillin-tazobactam concentration target attainment in children with cancer. <i>Pediatr Blood Cancer</i>. 2019;66(10):e27882. doi:10.1002/pbc.27882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31222911/pubmed" id="31222911" target="_blank">31222911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19832720">
<a name="19832720"></a>Saltoglu N, Dalkiran A, Tetiker T, et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. <i>Clin Microbiol Infect</i>. 2010;16(8):1252-1257. doi: 10.1111/j.1469-0691.2009.03067.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19832720/pubmed" id="19832720" target="_blank">19832720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28484510">
<a name="28484510"></a>Sartelli M, Catena F, Abu-Zidan FM, et al. Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. <i>World J Emerg Surg</i>. 2017;12:22. doi: 10.1186/s13017-017-0132-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/28484510/pubmed" id="28484510" target="_blank">28484510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17408306">
<a name="17408306"></a>Scheetz MH, McKoy JM, Parada JP, et al. Systematic review of piperacillin-induced neutropenia. <i>Drug Saf</i>. 2007;30(4):295‐306. doi:10.2165/00002018-200730040-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/17408306/pubmed" id="17408306" target="_blank">17408306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33340867">
<a name="33340867"></a>Seddik TB, Rabsatt LA, Mueller C, et al. Reducing piperacillin and tazobactam use for pediatric perforated appendicitis. <i>J Surg Res</i>. 2021;260:141-148. doi:10.1016/j.jss.2020.11.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/33340867/pubmed" id="33340867" target="_blank">33340867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25609660">
<a name="25609660"></a>Shaik S, Kazi HA, Ender PT. Rapid-onset piperacillin-tazobactam induced thrombocytopenia. <i>J Pharm Pract</i>. 2015;28(2):204‐206. doi:10.1177/0897190014566302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25609660/pubmed" id="25609660" target="_blank">25609660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45‐e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19809009">
<a name="19809009"></a>Shea KM, Cheatham SC, Smith DW, et al. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. <i>Ann Pharmacother.</i> 2009a;43(11):1747-1754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19809009/pubmed" id="19809009" target="_blank">19809009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19726163">
<a name="19726163"></a>Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. <i>Int J Antimicrob Agents</i>. 2009b;34(5):429-433. doi:10.1016/j.ijantimicag.2009.07.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/19726163/pubmed" id="19726163" target="_blank">19726163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shotwell.2016">
<a name="Shotwell.2016"></a>Shotwell MS, Nesbitt R, Madonia PN, et al. Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin-tazobactam in critically ill patients undergoing CRRT. <i>Clin J Am Soc Nephrol</i>. 2016;11(8):1377-1383. doi:10.2215/CJN.10260915.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simon.2019">
<a name="Simon.2019"></a>Simon RH. Cystic fibrosis: antibiotic therapy for pulmonary exacerbations. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33902072">
<a name="33902072"></a>Smith MJ, Boutzoukas A, Autmizguine J, et al. Antibiotic safety and effectiveness in premature infants with complicated intraabdominal infections. <i>Pediatr Infect Dis J</i>. 2021;40(6):550-555. doi:10.1097/INF.0000000000003034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/33902072/pubmed" id="33902072" target="_blank">33902072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society (SIS) and the Infectious Diseases Society of America (IDSA). <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31448789">
<a name="31448789"></a>Solórzano-Santos F, Quezada-Herrera A, Fuentes-Pacheco Y, et al. Piperacillin/tazobactam in continuous infusion versus intermittent infusion in children with febrile neutropenia. <i>Rev Invest Clin</i>. 2019;71(4):283-290. doi:10.24875/RIC.19002943<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31448789/pubmed" id="31448789" target="_blank">31448789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published correction appears in:<i> Clin Infect Dis</i>. 2015;60(9):1448]. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi: 10.1093/cid/ciu444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strange.2017">
<a name="Strange.2017"></a>Strange C. Parapneumonic effusion and empyema in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 28, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26400582">
<a name="26400582"></a>Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: A systematic review. <i>Neurology</i>. 2015;85(15):1332‐1341. doi:10.1212/WNL.0000000000002023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26400582/pubmed" id="26400582" target="_blank">26400582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22696019">
<a name="22696019"></a>Tamma PD, Turnbull AE, Milstone AM, Hsu AJ, Carroll KC, Cosgrove SE. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? <i>Clin Infect Dis</i>. 2012;55(6):799-806. doi: 10.1093/cid/cis545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/22696019/pubmed" id="22696019" target="_blank">22696019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26830215">
<a name="26830215"></a>Tamme K, Oselin K, Kipper K, et al. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock. <i>Acta Anaesthesiol Scand</i>. 2016;60(2):230-240. doi:10.1111/aas.12629.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/26830215/pubmed" id="26830215" target="_blank">26830215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8215266">
<a name="8215266"></a>Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW; Piperacillin/Tazobactam Skin and Skin Structure Study Group. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. <i>Antimicrob Agents Chemother</i>. 1993;37(8):1580-1586.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/8215266/pubmed" id="8215266" target="_blank">8215266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36545869">
<a name="36545869"></a>Tang Girdwood S, Hasson D, Caldwell JT, et al. Relationship between piperacillin concentrations, clinical factors and piperacillin/tazobactam-associated acute kidney injury. <i>J Antimicrob Chemother</i>. 2023;78(2):478-487. doi:10.1093/jac/dkac416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/36545869/pubmed" id="36545869" target="_blank">36545869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25124380">
<a name="25124380"></a>Terico AT, Gallagher JC. Beta-lactam hypersensitivity and cross-reactivity. <i>J Pharm Pract</i>. 2014;27(6):530‐544. doi:10.1177/0897190014546109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25124380/pubmed" id="25124380" target="_blank">25124380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29121839">
<a name="29121839"></a>Thabit AK, Grupper M, Nicolau DP, Kuti JL. Simplifying piperacillin/tazobactam dosing: pharmacodynamics of utilizing only 4.5 or 3.375 g doses for patients with normal and impaired renal function. <i>J Pharm Pract</i>. 2017;30(6):593-599. doi:10.1177/0897190016684453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29121839/pubmed" id="29121839" target="_blank">29121839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31427292">
<a name="31427292"></a>Thibault C, Lavigne J, Litalien C, Kassir N, Théorêt Y, Autmizguine J. Population pharmacokinetics and safety of piperacillin-tazobactam extended infusions in infants and children. <i>Antimicrob Agents Chemother</i>. 2019;63(11):e01260-19. doi:10.1128/AAC.01260-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/31427292/pubmed" id="31427292" target="_blank">31427292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tong.2004">
<a name="Tong.2004"></a>Tong MK, Siu YP, Yung CY, Kwan TH. Piperacillin/tazobactam-induced acute delirium in a peritoneal dialysis patient. <i>Nephrol Dial Transplant</i>. 2004;19:1341.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis. </i>2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22746695">
<a name="22746695"></a>Uzun G, Onem Y, Hatipoglu M, Turhan V, Mutluoglu M, Ay H. Piperacillin/tazobactam-induced neutropenia, thrombocytopenia, and fever during treatment of a diabetic foot infection. <i>Scand J Infect Dis</i>. 2013;45(1):73‐76. doi:10.3109/00365548.2012.697638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/22746695/pubmed" id="22746695" target="_blank">22746695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11733473">
<a name="11733473"></a>Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. <i>J Antimicrob Chemother.</i> 2001;48(6):881-885.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/11733473/pubmed" id="11733473" target="_blank">11733473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35426861">
<a name="35426861"></a>Van Der Heggen T, Dhont E, Willems J, et al. Suboptimal beta-lactam therapy in critically ill children: risk factors and outcome. <i>Pediatr Crit Care Med</i>. 2022;23(7):e309-e318. doi:10.1097/PCC.0000000000002951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/35426861/pubmed" id="35426861" target="_blank">35426861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27139161">
<a name="27139161"></a>VanDevanter DR, Flume PA, Morris N, Konstan MW. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. <i>J Cyst Fibros</i>. 2016;15(6):783-790. doi:10.1016/j.jcf.2016.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27139161/pubmed" id="27139161" target="_blank">27139161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1‐10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29102324">
<a name="29102324"></a>Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. <i>Lancet Infect Dis</i>. 2018;18(1):108-120. doi: 10.1016/S1473-3099(17)30615-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29102324/pubmed" id="29102324" target="_blank">29102324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24612982">
<a name="24612982"></a>Varghese JM, Jarrett P, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. <i>Int J Antimicrob Agents</i>. 2014;43(4):343-348. doi:10.1016/j.ijantimicag.2014.01.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/24612982/pubmed" id="24612982" target="_blank">24612982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14969569">
<a name="14969569"></a>Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. <i>Paediatr Drugs</i>. 2004;6(1):45-65. doi:10.2165/00148581-200406010-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/14969569/pubmed" id="14969569" target="_blank">14969569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.2019">
<a name="Vollmer.2019"></a>Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020249">
<a name="29020249"></a>Watkins RR, Deresinski S. Increasing evidence of the nephrotoxicity of piperacillin/tazobactam and vancomycin combination therapy-What is the clinician to do? <i>Clin Infect Dis</i>. 2017;65(12):2137‐2143. doi:10.1093/cid/cix675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29020249/pubmed" id="29020249" target="_blank">29020249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957‐1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.2017">
<a name="Weintrob.2017"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32030529">
<a name="32030529"></a>Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. <i>Intensive Care Med</i>. 2020;46(suppl 1):10-67. doi:10.1007/s00134-019-05878-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/32030529/pubmed" id="32030529" target="_blank">32030529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2022">
<a name="WHO.2022"></a>
<i>WHO AWaRe (Access, Watch, Reserve) Antibiotic Book</i>. Geneva: World Health Organization; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.2018">
<a name="Wingard.2018"></a>Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8383659">
<a name="8383659"></a>Wise R. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia. <i>J Antimicrob Chemother</i>. 1993;31(suppl A):97-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/8383659/pubmed" id="8383659" target="_blank">8383659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and Maternal Medication, Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. <i>Clin Infect Dis</i>. 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21814800">
<a name="21814800"></a>Yamagishi Y, Terada M, Ohki E, Miura Y, Umemura T, Mikamo H. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by <i>Pseudomonas aeruginosa</i>. <i>J Infect Chemother</i>. 2012;18(1):127-129. doi: 10.1007/s10156-011-0285-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/21814800/pubmed" id="21814800" target="_blank">21814800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25575030">
<a name="25575030"></a>Yang H, Zhang C, Zhou Q, Wang Y, Chen L. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. <i>PLoS One</i>. 2015;10(1):e0116769. doi: 10.1371/journal.pone.0116769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/25575030/pubmed" id="25575030" target="_blank">25575030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36186238">
<a name="36186238"></a>Zembles TN, Kuhn EM, Thompson NE, Mitchell ML. Extended infusion β-lactams for the treatment of gram-negative bacteremia in children. <i>J Pediatr Pharmacol Ther</i>. 2022;27(7):677-681. doi:10.5863/1551-6776-27.7.677<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/36186238/pubmed" id="36186238" target="_blank">36186238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22949297">
<a name="22949297"></a>Zobell JT, Waters CD, Young DC, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins. <i>Pediatr Pulmonol</i>. 2013;48(2):107-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information/abstract-text/22949297/pubmed" id="22949297" target="_blank">22949297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zosyn.2020.04">
<a name="Zosyn.2020.04"></a>Zosyn (piperacillin/tazobactam) in Galaxy container [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zosyn.2">
<a name="Zosyn.2"></a>Zosyn (piperacillin/tazobactam) vials [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; December 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9777 Version 518.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
